Effects of the alkaloids harmine, emetine, and sanguinarine on human cancer cells by Zhao, Lei
 
 
DISSERTATION 
 
 
 
submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
 
 
              presented by: Lei Zhao 
              Master of Medicine 
              born in Urumqi, China 
 
              Date of oral examination: 
 
 
 
 
 
The effect of alkaloid harmine, emetine, and  
sanguinarine on human cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    Referees:         Prof. Dr. Michael Wink 
                                             Prof. Dr. Jürgen Reichling 
ZUSAMMENFASSUNG  
 
Über 21000 Alkaloide konnten bisher identifiziert werden. Hiermit stellen sie die größte 
Gruppe der stickstoffhaltigen Sekundärstoffe dar. Viele dieser Alkaloide sind für Tiere oder 
Menschen giftig. Die medizinische Nutzung von Alkaloiden kann als Ausnutzung von 
Eigenschaften angesehen werden, die eigentlich aus ökologischen oder evolutionsbedingten 
Gründen entwickelt wurden. Während der letzten Jahrzehnte rückte vor allem das 
krebsbekämpfende Potential der Alkaloide in das Zentrum des Interesses. Mehrere Alkaloide 
werden seit über 40 Jahren als Krebsmedikamente genutzt.  
 
In dieser Studie wurde die Cytotoxozität der drei Alkaloide Harmin, Emetin und Sanguinarin 
in den menschlichen Krebszelllinien MCF-7, HeLa und SiHa ermittelt. Die Ergebnisse des 
MTT-Assays zeigten, dass diese Alkaloide eine zelluläre Cytotoxizität aufweisen und einen 
zeit- und dosisabhängigen Zellzyklusarrest induzieren. Telomere und Telomerasen stellen 
aufgrund ihrer speziellen Struktur oder ihrer krebsrelevanten Eigenschaften interessante Ziele 
für die Krebsforschung dar. Es konnte nachgewiesen werden, dass einige natürlich 
vorkommende Alkaloide die Aktivität der Telomerase inhibieren. In unserer Studie wurde 
zuerst untersucht, ob Harmin, Emetin und Sanguinarin menschliche Telomerase inhibieren 
können. Durch den TRAP-Assay konnte nachgewiesen werden, dass alle drei Stoffe die 
Telomeraseaktivität in den Zelllinien inhibieren können, wenn die Zellüberlebensrate nach 
der Behandlung auf 70% reduziert wurde. Ein Vergleich der Inhibitionsrate aller Alkaloide 
zeigte, dass Harmin eine stärkere Inhibition aufwied als Emetin oder Sanguinarin. Um die 
zugrunde liegenden Mechanismen zu verstehen wurde Harmin einer näheren Untersuchung 
in den zwei Krebszelllinien MCF-7 und HeLa unterzogen. Hierdurch konnten wir 
nachweisen, dass Harmin zwar in beiden Zelllinien die Telomeraseaktivität signifikant 
herabsetzt, aber die zugrunde liegenden Mechanismen durchaus unterschiedlich sind. Harmin 
induzierte eine Herunterregulierung der Expression von hTERT mRNA in MCF-7-Zellen. In 
HeLa-Zellen verursachte Harmin das alternative Splicing von hTERT, begleitet von einem 
Anstieg der nichtfunktionellen β-Splice-Form. Es wurde bereits gezeigt, dass Harmin DNA-
Schädigungen hervorruft. Diese Resultate konnten wir in unserer Studie bestätigen. Durch 
ein β-Galactosidase-Staining und mehrere Western-Blot-Analysen konnten wir beobachten, 
dass die kontinuierliche Gabe von Harmin DNA-Schädigung auslöst. Die behandelten MCF-
7-Zellen alterten schneller durch den p53/p21-Pathway. Zusammenfassend legen unsere 
Daten nahe, dass die Cytotoxizität von Harmin zumindest teilweise durch die Inhibition der 
menschlichen Telomerase bedingt ist.  
SUMMARY 
 
Over 21,000 alkaloids have been identified, which thus constitute the largest group among 
the nitrogen-containing secondary metabolites. Many alkaloids have shown their powerful 
toxicity towards animals or humans. The medicinal use of alkaloids could be regard as an 
exploitation of properties that originally had been selected and developed in an ecological or 
evolutionary context. During the past decades, more attention has been drawn on their 
anticancer potencies. A number of alkaloids have been used as anticancer drug over 40 years. 
 
In this study, the cytotoxicity of three alkaloids harmine, emetine, and sanguinarine were 
selected and evaluated in human cancer cells including breast cancer cell MCF-7, cervical 
cancer cell HeLa and SiHa. Results obtained from MTT assay showed that these alkaloids 
exhibited cellular cytotoxicity against human cancer cells and induce cell cycle arrest in 
dose- and time- dependent manner. Telomeres and telomerase have become interesting 
targets for anticancer research based on their special structure or cancer-associated character, 
some natural alkaloids have been identified are able to inhibit telomerase activity. In our 
study, we firstly investigated whether the alkaloid harmine, emetine, and sanguinarine were 
able to inhibit human telomerase. Data obtained from TRAP assay indicated that when the 
cell viability of each cell line was remaining around 70% after the treatment of each drug, all 
the compounds exhibited an inhibitory effect on human telomerase. Compared the inhibitory 
rate between each alkaloid, harmine initiated a greater reduction than that of emetine or 
sanguinarine. To elucidate the underlying mechanisms, harmine was especially selected and 
applied in parallel in two cancer cell lines MCF-7 and HeLa in further research. We have 
found that although harmine could significantly inhibit the telomerase activity in both cell 
lines, the mechanisms were quite different. Harmine induced a down-regulation of the 
expression of hTERT mRNA in MCF-7 cells, whereas it regulated the hTERT alternative 
splicing accompanied by an increase of the non-functional β splice form in HeLa cell. 
Harmine has been documented is able to trigger DNA damage, we have obtained the 
consistent results in our study as well. By applying β-galactosidase staining and a series of 
western blotting analysis, we observed that the chronic treatment of harmine initiated a DNA 
damage response, and the treated MCF-7 cells eventually entered an accelerated senescence 
status through p53/p21 pathway. Taken together, our data suggest that the cytotoxicity of 
harmine might be generated, at least partially, by the inhibitory effect on human telomerase.    
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1 INTRODUCTION 
 
1.1 ALKALOIDS  
 
1.1.1 Introduction 
 
Plants produce plenty of secondary metabolites (SM), the alkaloids are one of the most 
diverse groups of SM found in living organisms and have a series of structure type (Roberts 
and Wink, 1998; Wink, 2007; 2008). The first alkaloid, morphine, was identified from the 
opium poppy, Papaver somniferum by Sertürner in 1806 (Kutchan, 1995). To date, over 
21,000 alkaloids have been identified (Wink, 2007).  
 
1.1.2 Classification of alkaloids 
 
Alkaloids are typical nitrogen containing ring structures. The position of nitrogen can be 
different depending on the class of alkaloids. In general, they have definite melting points 
and have a bitter taste. Compared with other natural products, alkaloids can be easily isolated 
due to their structure in which the nitrogen makes the compound basic, and the compounds 
exist in plants as a salt. Thus, alkaloids are often extracted with water or mild acid and then 
recovered as crystalline material after treatment with a base (Manske and Holmes, 1965).  
 
Alkaloids are a diverse group of chemical constituents. The criteria currently for alkaloid 
classification are: the structure and other chemical features of the alkaloid molecule, the 
biological origin, and the biogenetic origins (Roberts and Wink, 1998). There is no unified, 
taxonomy principle to classify all alkaloids, but it is possible to recognize four groups 
(Roberts and Wink, 1998): 
1. Alkaloids derived from amino acids such as arginine, lysine, tryptophan, and so on. 
2. Purine alkaloids, such as the xanthine caffeine 
3. Aminated terpenes, e.g., the diterpene aconitine or the triterpene solanine 
4. Polyketide alkaloids where nitrogen is introduced into a polyketide carbon skeleton as 
in coniine and the coccinellines 
Alkaloids constitute the largest group among the nitrogen-containing SM including 700 non-
protein amino acid, 100 amines, 60 cyanogenic glycosides, 100 glucosinolates, and 150 
alkylamides (Wink, 2007; 2008).  Alkaloids are widely distributed in plant kingdom, 
especially within the flowering plants. Recently, an increasing number of them have been 
found in animals, insects, marine organisms, microorganisms, and lower plants (Wink, 1993; 
                                                                                                                                  Introduction 
                                                                                                                                                  2                                                                                                                                                      
1999a; 1999b). The distribution of alkaloids are restricted in plants, microbial, animal species, 
and the organisms where these constituents have their own genetically defined alkaloid 
pattern, which may be useful under certain circumstances as chemical characters in 
systematic (Wink, 1988; 2008; Roberts and Wink, 1998).  
 
1.1.3 Cytotoxicity of alkaloids and the associated molecular modes of action 
 
1.1.3.1 Cytotoxicity of alkaloids 
 
Many alkaloids have shown their powerful toxicity on animals or humans. Most of the lethal 
alkaloids fall into the class of neurotoxins (Wink, 2008). And some act on the other different 
organs. For example, pyrrolizidine alkaloids which occur in Senecio plants will cause hepatic 
disease within a few weeks in horses and cattle (Wink, 1993; Elliott et al., 2005). The 
steroidal alkaloids induce embryo mortality in two fish species due to structural or functional 
abnormalities in the early development stages (Crawford and Kocan, 1993). A summary of 
cytotoxic properties of alkaloids was reviewed (Wink, 1993; 2007). Vinblastine, vincristine, 
colchicine and taxol are particularly famous in their toxicity on the mitotic spindles (Wink, 
2007), and they have been used in chemotherapy. A cytotoxic effect can also be generated 
when cell membranes become leaky (Wink, 2008). In general, biomembranes are almost 
impermeable for ions and polar molecules, such prevention can be achieved through specific 
transport proteins including ion channels, pores, or carrier proteins (Roberts and Wink, 1998).  
If the transport of metabolites has to proceed against a concentration gradient, the transport 
processes must be directly or indirectly energized. These complex transport systems have 
become targets of many natural products (Roberts and Wink, 1998).  
 
1.1.3.2 Molecular modes of action 
 
Alkaloid cytotoxicity can be generated through interference with important molecular targets 
present in a cell (Fig.1). The modulated molecular target can negatively influence its 
communication and the associated network. Subsequently, the metabolism and the function 
of cells, tissues, organs, and even the complete organism can be literally affected and an 
overall toxic effect occurs (Wink, 2008). The main targets include DNA, RNA and some 
associated enzymes, protein biosynthesis, protein conformation, biomembranes and 
membrane proteins (Wink, 2007).  
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1.1.3.2.1 Specific interactions 
 
Compared with plants, the nerve cells are unique cells present in animals. Therefore, 
neuronal signal transduction, and the endocrinal hormone system can be targeted by plants 
particularly (Wink, 1993;2000;2008). Compounds that interfere with these targets are usually 
not toxic for the plants producing them. Many alkaloids were characterized as specific 
modulators and have been modified during evolution. The modification enable these 
compounds mimic endogenous ligands, hormones, or substrates (Wink, 1988;1993;2000). 
Some deadly alkaloids are strong neurotoxins that were selected for defense against animals 
(Wink, 1993;1998;2000; Roberts and Wink, 1998). A summary of the potential neuronal 
targets that can be affected by alkaloids is available in the review (Wink, 2008).  
 
Neurotransmitters derive from amino acids, and most of them are amines which become 
protonated under physiological conditions (Wink, 2008). It has been demonstrated that 
several alkaloids have structural similarities to those neurotransmitters due to alkaloids also 
derive from amino acids. Thus, they can be considered as neurotransmitter analogs (Wink, 
2008). These structural neurotransmitter-like alkaloids can bind to neuroreceptors to activate 
or inactivate them. In addition, some ion channels, such as the Na+, K+, and Ca+ are also 
important targets, they have been reported to be inhibited or induced by several known 
alkaloids (Wink, 1993;2000;2008). Neuronal signal transduction is very critical in an animal, 
any disturbance can lead to organ’s dysfunction, such as mind-altering, or hallucinogenic 
properties (Wink, 1993; Roberts and Wink, 1998).  
  
1.1.3.2.2 Interactions with DNA, RNA, and associated enzymes  
 
1) DNA alkylation and intercalation 
 
As DNA encodes all RNAs, proteins which are important for metabolism and development 
of an organism, therefore, DNA is an highly attractive target (Wink, 1993; Roberts and Wink, 
1998). The reaction can happen in two patterns: DNA alkylation and intercalation. Alkylating 
agents can form covalent bonds with the host DNA onto N6 guanine, which eventually lead 
to DNA strand breaks (DSBs). These molecules include cisplatin, nitrosourea derivatives and 
nitrogen mustard. DSB can be repaired by the enzyme alkylguanine-DNA alkyl transferase 
(AGT) through a transferring action in which the alkyl group could be removed from the 
lesions stoichiometrically to a cysteine in its active site (Vaidyanathan and Zalutsky, 2004). 
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If the repair process fails, mutation may happen, consequently, transitions or transversions 
may occur within nucleotides.  
 
 
Fig 1. Molecular targets in animal and human cells that can be affected by natural products 
(Wink, 2007). 
 
 
Intercalation is a non-covalent reaction between small molecules and DNA. Small molecules 
that intercalate between stacks of DNA bases have been investigated for more than 40 years, 
due to the activity of such molecules as therapeutic drugs or as mutagenic agents (Persil and 
Hud, 2007). Many of intercalating compounds are planar and lipophilic, which facilitate 
these compounds insert between stacks of base pairs and stabilize the double stranded DNA, 
whereby to disturb DNA replication or transcription (Wink, 2007). The intercalation also 
takes place in RNA. RNA is basically single stranded. However, most RNA molecules have 
double-stranded stem structures due to complementary base pairing. These double stranded 
regions can also be intercalated (Wink, 2007). Intercalation often induces a frameshift 
mutation, which changes the sequence of corresponding amino acid to trigger some 
detrimental effect on the individual cell or organ (Wink, 2007). Some toxic alkaloids have 
intercalating characters, such as isoquinoline, quinoline, and indole alkaloids, which are 
synthesized from the aromatic amino acids phenylalanine, tyrosine, and tryptophan (Wink et 
                                                                                                                                  Introduction 
                                                                                                                                                  5                                                                                                                                                      
al., 1998; Wink, 1999b). A review of alkaloids that interfere with DNA, RNA, and associated 
enzymes is available (Wink, 2007).    
        
2) DNA topoisomerase I and II 
 
DNA Topoisomerase is an enzyme that alters the supercoiling of double-stranded DNA. 
DNA Topoisomerase acts by transiently cutting one (topoisomerase I) or both strands 
(topoisomerase II) of the DNA. DNA topoisomerase I and II are ubiquitous enzymes that 
play an essential role in transcription, replication, chromosome segregation, and DNA repair. 
The inhibitions of these enzymes usually result in cell-cycle arrest and cell death by 
apoptosis (Wink, 2007). Topoisomerase I is an important target in tumor cell, it can be 
targeted by some alkaloids, such as quinazoline–quinoline (Ma et al. 2004), coralyne (Gatto 
et al., 1996), and pallidine (Cheng et al., 2008) which turn these enzymes into cellular 
poisons.  
 
The mechanism of the inhibition of topoisomerase caused by compounds has been 
documented. These compounds either directly inhibit its catalytic activity (Ganguly et al., 
2007; Chene et al., 2009) or stabilize the transient “cleavable ternary complexes” by 
preventing strand resealing (Wink, 2007), whereby the cleavable complexes are converted to 
lethal lesions when the cell tries to use the damaged DNA tempelate for replication (Denny, 
1997; Bailly, 2000). Data obtained from different groups showed that the DNA intercalating 
alkaloids cryptolepine (Bonjean et al., 1998; Dassonneville et al., 1999), matadine, and 
serpentine can tightly bind DNA. These three compounds stabilize the DNA-topoisomerase 
II complex and stimulate the cutting of DNA by topoisomerase II (Dassonneville et al., 1999; 
Wink, 2007). This observation supports the 'drug stacking' model of interaction, where 
inhibitors with a 'deep intercalation mode' are responsible for topoisomerase I-mediated 
cleavage and those with an 'outside binding mode' are responsible for topoisomerase II-
mediated cleavage (Denny, 1997). A number of alkaloids affect both enzymes, such as 
benzophenanthridine (Okamoto et al., 2005), indenoquinolone, and acridine alkaloids 
(Denny, 1997; Wink, 2007).  
 
3) Telomeres and telomerase 
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The ends of linear eukaryotic chromosomes contain specialized structures termed telomeres. 
Human telomeres consist of tandem repeats of the hexameric sequence TTAGGG. These 
repeats help maintain chromosomal integrity and prevent them from degradation, 
recombination, and being mistaken for DNA double-strand breaks (Shay and Wright, 2005). 
A loss of telomeric DNA is found with each cell division due to the end replicative problem 
(Watson, 1972) and eventually lead to replicative senescence. Almost all eukaryotic cells 
depend on telomerase, a ribonucleoprotein enzyme responsible for adding telomeric DNA 
onto 3’ ends of chromosomes (Greider and Blackburn, 1985) for the de novo synthesis of 
telomeres.  
 
Telomeres and telomerase become interesting targets for anticancer research based on their 
special structure or cancer-associated character. Recently, some natural alkaloids were found 
to able to inhibit telomerase. These alkaloids include ellipticine (Garbett and Graves, 2004), 
cryptolepine, neocryptolepine (Guittat et al., 2003; Wink, 2007). These alkaloids affect 
targets either by triggering a DNA damage response via “drug stacking” model of interaction 
with telomeres, or by inhibiting of telomerase enzymatic activity. More details have been 
described in chapter 1.2.    
 
1.1.3.2.3 Cytoskeleton 
 
The cytoskeleton of eukaryotic cells pervades the cytoplasm. It consists of three broad 
classes of proteins: actin filaments, microtubules and intermediate filaments. The regulation 
of cytoskeletal activity plays a role in cell maintenance, cell division, and apoptosis. During 
cell division, the duplicated chromatids are separated and pulled apart into daughter cells; 
such process is completed by a complex interaction of microtubules. Microtubules are 
elements of cellular cytoskeleton and are polymers of tubulin (Wink, 2007). It has been 
described that GTP promotes protofilaments forming; several protofilaments are assembled 
into microtubules. On the other hand, the microtubules are disassembled when GDP is 
dominant (Wink, 2007).  Any alteration on microtubule dynamics leads to cell cycle arrest at 
mitosis and eventually apoptosis (Zhou and Giannakakou, 2005). The cell division in cancer 
cells is faster than differentiated normal cells. Therefore, to inhibit the activity of microtubule 
becomes a major target for anticancer agents (Wink, 2007). These drugs have a wide 
spectrum of activity against hematological and solid tumors. It has been demonstrated that 
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most of anticancer drugs that come from nature can interfere with microtubules (Wink, 2007). 
The bis-monoterpene indole alkaloids vinblastine and vincristine are well-known examples. 
The interactions of these alkaloids with tubulin heterodimers and microtubules have been 
studied extensively; they can interfere with microtubules dynamics in terms of special 
binding sites (Lobert et al., 1996; Wink, 2007).  
 
1.1.3.2.4 Induction of apoptosis 
 
A number of toxins have been identified are able to induce apoptosis. The apoptosis appears 
to be the major mechanism of cytotoxicity caused by SM. These SM include polyphenols, 
terpenoids, and also alkaloids (Wink, 2007). Those SM with apoptotic properties have drawn 
much attention in anticancer drug development. As documented, several protoberberine and 
benzophenanthridine alkaloids, indole alkaloids induce apoptosis (Wink, 2007). These 
compounds usually intercalate DNA, and subsequently inhibit DNA and RNA polymerase, 
topoisomerase, and even ribosomal protein biosynthesis (Wink et al., 1998; Wink, 2007), or 
bind to tubulin/microtubules to behave as spindle poisons. 
 
1.1.3.2.5 Interactions with ABC transporters and cytochrome p450 
In order to overcome the intestinal and blood brain barrier, plants have evolved lipophilic 
toxins that can enter body by diffusion. On the opposite side, animals have developed 
powerful detoxification mechanisms to cope with these toxins (Wink, 2007). One of the 
mechanisms is mediated by an enzyme family, known as cytochrome p450 oxidase. This 
pathway consists of two phases. In phase I, a group of enzymes, known as cytochrome p450 
oxidases (CYP) act on lipophilic toxins by introducing hydroxyl groups to make them more 
hydrophilic (Guengerich, 2001). In phase II, the hydroxylated compounds are conjugated 
with polar molecules. Then these conjugates are eliminated by the kidneys and urine. 
 
Another well-known pathway is mediated by the ATP binding cassette (ABC) transporters. 
These transporters are present in most of cells and especially active in intestinal, liver, kidney, 
and endothelial (Nielsen and Skovsgaard, 1992; Nooter and Stoter, 1996). These ATP-driven 
transporters can pump lipophilic compounds out of cell, either back to the gut lumen or into 
the blood system. In such a way, the intracellular concentration of potentially toxic 
compounds can be reduced (Wink, 2007). 
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1.1.4 The chemotherapeutic effect of alkaloids 
 
Cancer comprises a large variety of malignant tumors that can affect nearly all organs of the 
body. From a primary tumor, metastases can spread to other tissues and organs, which is fatal 
if a tumor destroys the function of a vital organ. Treatment includes surgery, radiotherapy 
and chemotherapy. In the clinic, doctors and researchers conduct clinical research in distinct 
segments called phases. Each phase of a clinical trial is designed to provide different 
information about the new treatment, such as the dose, safety, and efficacy. After promising 
treatments are explored in animal and/or laboratory studies, researchers perform clinical trials. 
There are three phases for clinical trials. The goal of a phase I clinical trial is to prove that a 
new drug or treatment, which has proven to be safe for use in animals, may also be given 
safely to people. Phase II clinical trials are designed to provide more detailed information 
about the safety of the treatment, in addition to evaluating its efficacy. The goal of phase III 
clinical trials is to take a new treatment that has shown promising results among a small 
number of patients with a particular disease and compare it with the current standard for that 
specific disease. In this phase, data are gathered from large numbers of patients to determine 
whether the new treatment is more effective and possibly less toxic than the current standard 
treatment. 
 
Cancer cells usually divide much faster than ‘normal’ cells. Therefore, compounds that stop 
cell division (e.g. alkaloids, such as vinblastine, vincristine, paclitaxel, docetaxel, 
camptothecin, colchicine, demecolcine, or the lignan podophyllotoxin) or cytotoxic 
compounds that directly kill cancer cells are the mainly employed means of chemotherapy 
(Roberts and Wink, 1998; Wink et al., 2005; Wink, 2007). Whereas vinblastine, demecolcine 
and podophyllotoxin inhibit the polymerization of tubulin to microtubules, paclitaxel 
stabilizes the microtubule complexes. Camptothecin mainly acts as an inhibitor of DNA 
topoisomerase I, the podophyllotoxin derivatives (such as etopophos) inhibit topoisomerase 
II. Inhibition of polymerization or dissociation of microtubules and DNA topoisomerase stop 
the multiplication of healthy and tumour cells (Wink et al., 2005; Wink, 2007). To date, more 
than 50 drugs are available for cancer therapy, nevertheless, the need for more effective 
anticancer agent remains.  
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1.1.5. Alkaloids in medicine 
 
1) Harmine 
 
Harmine is the most representative naturally occurring β-carboline alkaloid, which was 
originally isolated from Peganum. harmala L, mainly occurring in seeds and roots (Budavari, 
1989; Roberts and Wink, 1998; Wink and Wyk, 2008). More recent study showed that 
harmine is found as 4.3 % (w/w) in dry seeds and as 2.0 % (w/w) in root, respectively 
(Herraiz et al., 2009).       
                            
                                                
                                                                    harmine  
 
Harmine is inhibitor of monoamine oxidase (MAO) (Kim et al., 1997; Roberts and Wink, 
1998), which has been identified as early as 1965 (Burger, 1965). MAO is an enzyme 
essential for the metabolism of neurotransmitters. Harmine is a known hallucinogenic 
substance since it binds to serotonin receptor, and whereby to enhance serotonin activity 
(Roberts and Wink, 1998; Wink, 2007; Wink and Wyk, 2008). Plants containing it are 
famous drugs in S America (including ayahuasca) (Wink and Wyk, 2008). In vitro studies 
showed that harmine can intercalate DNA (Taira et al., 1997; Roberts and Wink, 1998; Wink, 
2007), and in such a way to compromise DNA replication, or to inhibit the associated 
enzymes such as topoisomerases (Funayama et al., 1996; Wink, 2007). More specific 
research demonstrated that harmine inhibits the activity of topoisomerase I, whereas it has no 
effect on topoisomerase II, even at a high concentration of 600 µM (Cao et al., 2005; Wink, 
2007; Jimenez et al., 2008). It has been reported that harmine inhibited several cyclin-
dependent kinases such as Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 (Song et al., 2002; 
Song et al. 2004), suppressed the growth of Leishmania parasites with a moderate selectivity 
(Di-Giorgio et al. 2004), and acts as a cell-type-specific regulator of the key adipogenic 
factor PPARγ (Waki et al., 2007).  
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2) Emetine 
 
Emetine is the main alkaloid in Cephaelis acuminata, which belongs to isoquinoline 
alkaloids group. Emetine has been used as a second choice in the treatment of severe 
intestinal amoebiasis and hepatic amoebiasis since 1912 (Vedder, 1912). It is also used in 
low dose as an expectorant drug with secretolytic and secretomotoric properties (Roberts and 
Wink, 1998). 
The first report stating the effectiveness of emetine in the treatment of cancer appeared in 
1918 (Lewisohn, 1918) and was revived in 1969 (Panettiere and Coltman, 1971). Nowadays, 
emetine is an important tool in cell biology and in vitro pharmacological studies when 
inhibition of protein biosynthesis is required (Möller and Wink, 2007b). 
 
 
                                     
                                                             emetine 
 
Emetine is well known to inhibit eukaryotic protein biosynthesis by blocking the elongation 
process (Grollman, 1968; Grollman and Huang, 1973) and was described to intercalate DNA 
(Wink, 2003). Like many other protein biosynthesis inhibitors, emetine has the ability to 
induce apoptosis in human tumour cells (Kochi and Collier, 1993; Bicknell et al., 1994). 
 
3) Sanguinarine 
 
Sanguinarine is from the group of benzo[c]phenanthridine alkaloids. It is extracted from 
Sanguinaria canadensis (Papaveraceae). It has been discovered in milk of lactating cows that 
were feeding on plants containing this alkaloid (Wink and Wyk, 2008). Sanguinarine is used 
in toothpastes and mouthwashes (Roberts and Wink, 1998; Wink and Wyk, 2008). 
 
                                                
 
                                                         sanguinarine     
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It has been identified that sanguinarine modulates a number of molecular targets such as: 
intercalation to DNA, complexation of SH groups in enzymes, inhibition of esterases, Na+/K+ 
ATPase, alanine aminotransferase, human sputum elastase and others. Some of affected 
organisms are: several Escherichia and Aerobacter species, Bacillus anthracis, Trichomonas 
vaginalis, several Vibrio species. It is also active against several oral microbial isolates, such 
as several Actinomyces, Bacteroides, and Propionibacterium species. Furthermore, 
sanguinarine has adrenolytic, sympatholytic, anti-inflammatory, cytotoxic, antifungal, and 
local anesthetic effects (Roberts and Wink, 1998; Wink, 2007; Wink and Wyk, 2008). 
 
1.2 TELOMERE BIOLOGY 
 
1.2.1 Telomere hypothesis 
 
In 1938, a geneticist Müller for the first time named the structure which locates at the end of 
chromosomes “terminal gene”, afterwards, the name was modified as “telomere” from the 
Greek terms “telos” (end) and “meros” (part) (Müller, 1938). Müller observed that the ends 
of irradiated chromosomes of fruit flies (Drosophila melanogaster) did not reveal the 
alteration which often appeared in the other genome, such as deletions or inversions. This 
finding has been traced in molecular biology and genetics study for decades ever since. It 
was about two years after Müller found telomeres, Barbara McClintock from the University 
of Missouri, who worked in corn genetics, claimed that telomeres direct a crucial role in the 
integrity of chromosomes (McClintock, 1941). However, the telomere sequence and its 
associated proteins were for the first time identified from Tetrahymena by Elizabeth H. 
Blackburn et al. in 1978. In their study, they found that telomere consists of tandem repeat 
DNA sequences, and it is a highly conserved structure at each end of chromosome 
(Blackburn and Gall, 1978). From that moment on, telomeres have been cloned and 
sequenced from diverse organisms, such as ciliates, yeast, plants, and mammals (Table 1). 
After comparing with the telomeric sequences identified from different organisms, people 
found that the telomeric DNA sequences are very similar and they are all made up of variable 
number of tandemly repeated, simple, GC-rich sequences (Blackburn and Challoner, 1984a; 
Moyzis et al., 1988).  
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               Table 1. Telomere sequence in different organisms 
 
                   Organism                                              telomeric repeat sequence (5’-3’) 
                 Vertebrate        
                        Homo sapiens                                                            TTAGGG (Blackburn 1991) 
                  Invertebrates  
                     Cassiopeiae sp.                                                                  TTAGGG (Ojimi 2009) 
                     Ampedus sanguineus                                                 TTAGG (Frydrychova 2004) 
                     Caenorhabditis elegans                                               TTAGGC (Cangiano 1993) 
                   Fungi  
                        Schizosaccharomyces pombe                                  G2–8TTAC(A) (Murray 1986) 
                    Saccharomyces castellii                                        TCTGGG(TG)1-4 (Cohn 1995) 
                     Aspergillus oryzae                                      TTAGGGTCAACA (Kusumoto 2003) 
                     Neurospora crassa                                                   TTAGGG (Schechtman 1990)  
                 Plants  
                     Nicotiana tabacum                                                            TTAGGG (Weiss 2002)  
                     Solanum lycopersicum                                                TT[T/A]GGG (Ganal 1991) 
                   Strombosia pustulata                                                TTTTAGGG (Teixeira 2005) 
                  Algae 
                     Cyanidioschyzon merolae                                      AATGGGGGG (Nozaki 2007) 
                     Chlamydomonas reinhardtii                                    TTTTAGGG (Petracek 1990) 
                      
               
The end replication problem was first proposed by Watson in 1972. He described that during 
the process of replication, after the double strands are separated by helicase, the replication 
on the leading strands can be elongated continuously all the way to the end of template 
following 5’-3’ direction. But on the opposite lagging strand, replication is carried out in 
segments fashion, called Okazaki fragments. A problem occurs when the lagging strand nears 
the end of a chromosome. There is no DNA sequence to serve as template for the next 
Okazaki fragment to fill in the gap between the last Okazaki fragment and the end of a 
chromosome. Thus, the extreme end of chromosome is not replicated. This incapability may 
lead to the loss of essential genes eventually on the end of a chromosome. Fortunately, this 
problem was solved by the existence of telomeres. The lengths of telomere are quite different 
between species, from approximately 300 - 600 base pairs in yeast (Shampay et al., 1984) to 
25 - 150 kilo base pairs in mice (Kipling and Cooke, 1990). Human telomere length is in the 
range of 10-15 kbp in normal somatic tissues of young persons, 7–8 kbp at old ones and the 
shortest of 1.5–2 kbp in crisis cells (Greider, 1996; Martens et al., 1998; Meyerson, 2000; 
Shay and Wright, 2005). Approximately 50-200 bp of telomeres are lost in every cell 
division due to the end replication problem (Fig 2) (Watson, 1972; Harley et al., 1990). The 
telomeric DNA does no carry any complex genomic information, but instead a simple, GC-
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rich sequence repeated dozens even thousands of times at each end of chromosome.  The 
telomeric DNA can bind specific proteins, which cap the chromosome ends either directly 
(Horvath et al., 1998) or by inducing a special DNA structure like T-loop (Griffith et al., 
1999; Cech, 2000). It has demonstrated such protection involve into several essential 
biological regulations, protecting chromosomes from recombination, end-to-end fusion, and 
been recognized as damaged DNA. Telomeres also provide a means for complete replication 
of chromosomes, contribute to the functional organization of chromosomes within the 
nucleus, and participate in the regulation of gene expression (McClintock, 1941; Pologe 
1988). 
 
 
                                    Fig 2. End replication problem (Rubin, 2002) 
 
The link between cell viability and telomere length has now been established in a number of 
different organisms. During cell proliferation, the telomeres get progressively shortened of 
50-100 base pairs in each round of replication (Harley et al., 1990). According to Hayflick 
limit theory (Hayflick, 1965), this shortening in normal cell serves as a molecular clock that 
controls the replicative capacity of individual cells. After a certain numbers of cell divisions, 
the telomere length becomes extremely short, and then cells stop dividing and undergo 
replicative senescence.  
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1.2.2 Telomere structure and associated regulation 
 
1.2.2.1 T loop 
 
Human telomeres consist of variable number of tandem repeats of the TTAGGG sequence 
and a group of specific proteins. Electron microscopy analysis of psoralen cross-linked 
human telomeric DNA revealed abundant large t loops with a size distribution consistent 
with their telomeric origin. At the 3’ end, the G rich overhang invades into the duplex 
telomeric DNA repeat array to form a D-loop and T-loop structure in vitro (Greider, 1999; 
Griffith et al., 1999). This structure appears to protect the telomeres from end to end fusion 
with other chromosomes and from cell cycle checkpoints that would otherwise recognize the 
telomeres as chromosome breaks requiring repair (Blackburn, 1984b; 1991). 
 
Telomeres are nucleoprotein complexes, consisting of DNA repeat and a series of proteins 
(Moyzis et al., 1988; Blackburn, 2000). Some associated proteins bind directly onto the 
T2AG3 repeats; and the others perform the regulation via protein-protein interaction (Fig 3). 
 
 
 
Fig 3. Telomere T-loop structure with telomere-specific binding proteins. The single-stranded 
DNA at the end of the telomere is able to invade and anneal with part of the duplex DNA (D-loop) in 
the same telomere, with the overall result being a telomere (T)-loop. Several proteins bind directly to 
telomeric DNA, whereas others are associated with telomere via protein-protein interaction 
(Neumann and Reddel, 2002). 
 
In human beings, TRF1 and TRF2 proteins specifically bind double stranded telomere 
sequences via a helix motif (Chong et al., 1995; Bilaud et al., 1996). Both of TRF1 and 
TRF2 and their associated proteins, such as RAP1p, tankyrase, KU are primarily responsible 
for stabilizing the complex and forming the T-loop. It has been demonstrated that TRF1 and 
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TRF2 are involved in regulating telomere length, displaying an inhibitory effect on telomere 
maintenance in vivo (Granger et al., 2002). In some research, the over-expression of TRF1 
and TRF2 led to an eventual shortening of telomere in telomerase positive cells 
(Smogorzewska et al., 2000; Ancelin et al., 2002). Furthermore, results obtained from 
different studies showed that TRF1 mainly regulates telomere length (van Steensel and de 
Lange, 1997), whereas TRF2 appears to be particularly abundant at the base of the T-loop 
and is important for its stabilization and formation (Stansel et al., 2001). The proteins which 
are involved in telomere regulation in vivo are listed (Table 2). 
 
Table 2, Telomerase-/telomere-associated proteins and their interaction (Olaussen et al,. 2006) 
 
 Factors                                      Name in human        Effect on telomere                      Interactions with  
 Telomere specific protein           
  
Telomerase accessory factor       EST1A,EST1B                                                                       Telomerase 
 
G-tail binding factors                   POT1                          Binds T2AG3 using OB-fold              TRF1, TRF2, PTOP, TIN2 
                                                                                                                                                    Tankyrase 1 
   Duplex                                         TRF1                           Binds telomeres,                                 POT1, TRF2, PTOP, TIN2 
                                                                      negative length regulator                   PINX1, TANK1/2, Ku, BLM 
                                                                                                                                                          
                                                         TRF2                           Binds telomeres,                                POT1, TRF1, hRAP1, 
PARP2,  
                                                                      negative length regulator,                  TIN2, MRN, ERCC1/XPF, 
                                                                      role in T-loop,                                    WRN, BLM, Ku, ATM 
                                                                                              chromosome stability 
 
Proteins indirectly                        hRAP1                        Length regulator                                 TRF2, MRN 
binding telomere                          TANK1/2                    PARP activity, TRF1                         TRF1 
                                                                                          ribosylation, positive length 
                                                                                          regulator 
                                                     TIN2                            Positive length regulator                    TRF1, TRF2 
                                                     PINX1                         Telomerase inhibitor                          TRF1, TIN2 
 
Others  
   DNA repair proteins                    Ku70/Ku86                    NHEJ, telomere localization,             Telomerase, TRF1, TRF2 
                                                                                               negative length regulator, 
                                                                                               telomere capping  
                                                        DNAPKcs                      NHEJ, telomere localization. 
                                                                                               telomere capping 
                                                        Mre11/Rad50/Nbs1       Recombination, NEJ                          TRF2 
                                                        ERCC1/XPF                  NER                                                   TRF2 
 
   Checkpoint proteins                    ATM                               DNA damage signaling                     TRF1, TRF2                             
                                
 
 
1.2.2.2 G-quadruplex 
 
The non-coding repeats of guanine-rich DNA as present in the 3’-overhang of human 
telomeres, have been shown to form tetrastranded DNA structures termed G-quadruplexes. 
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So far, only two types of intramolecular G-quadruplex, basket- and propeller-type, have been 
identified in human telomeric sequences in presence of sodium or potassium ions (Wang and 
Patel, 1993; Parkinson et al., 2002). It has been calculated that the human genome contains 
as many as 376,000 potential G-quadruplexes forming sequences (Huppert and 
Balasubramanian, 2005; Todd et al., 2005). These sequences are concentrated in promoter 
regions (Rawal et al., 2006; Hershman et al., 2008), introns (Huppert and Balasubramanian, 
2005), 5’ and 3’ UTRs (Huppert et al., 2008), and at the ends of eukaryotic chromosomes 
(Mergny et al. 2002; Cuesta et al. 2003), suggests that G-quadruplexes may have importance 
function in vivo. Based on the knowledge that folded G-quadruplex structures are inactive 
substrates for telomerase (Zahler et al., 1991), some small molecules, for instance the 
cationic porphyrin TMPyP4 (De Cian et al. 2007; Reed et al. 2008), the anionic porphyrin N-
methyl mesoporphyrin (NMM) (Arthanari et al., 1998), and  telomestatin (SOT-095) (De 
Cian et al., 2007; Reed et al., 2008) have been developed as telomerase inhibitors by 
stabilizing G-quadruplex-folded structures in the 3’ overhangs of telomeric DNA. All these 
interactions were performed in vitro so far, the development of G-quadruplex-specific 
antibodies generated by in vitro evolution may provide key tools for target validation 
(Schaffitzel et al., 2001; Fernando et al., 2008), while the design and synthesis of new high 
affinity G-quadruplex ligands will provide new drug candidates and molecular probes 
(Luedtke, 2009). 
 
1.2.3 Telomerase 
 
Telomerase is a cellular ribonucleoprotein complex responsible for synthesizing and adding 
telomeric repeats onto the 3’ end of chromosomes (Blackburn et al., 1989; Le et al., 2000). It 
is a slow metabolic protein with a half-life over 24 hours (Holt et al., 1996b). The core of the 
enzyme is composed of two major components: an enzymatic reverse transcriptase, in human 
called hTERT and an RNA component, in human hTR, which contains a 11-bp sequence 
(CAAUCCCAAUC) complementary to the telomeric single strand overhang. The telomerase 
uses its RNA component to serve as a template to synthesize telomeric DNA repeats 
(TTAGGG)n together with the catalytic activity of its protein subunit. The complete telomere 
elongation reaction includes four events (Fig 4): 1) telomere end recognition, 2) RNA 
template alignment, 3) elongation and 4) translocation. First, the RNA template recognizes 
the end of telomeres via an anchor site which locates in hTERT, and then the 11-base 
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sequence serves as template to synthesis the telomeric DNA. In the end, the complementary 
strand is completed by DNA polymerase. Each repeat can be achieved via a “slippage” 
mechanism, during which one repeat is synthesized, the enzyme slips along and repositions 
itself at the new end of chromosome and repeat the process.                                                                                                                            
 
 
 
 
Fig 4. Model for elongation of telomere by telomerase. Human hTR consists of 11-basepairs as a 
template. After recognition of the single strand 3’overhang GTTAGG by telomerase, some 
nucleotides are hybridized to the CAAUCC sequence in the RNA, and then the sequence GGTTAG is 
synthesized at a time. Once a repeat is synthesized, the enzyme translocates to a new end and the 
process is repeated over and over again (Granger et al., 2002). 
 
It was demonstrated that telomerase is actually one of the critical enzymes to make cells 
immortal; the activity is tightly linked to tumor malignancy, irrespective of the tissue type. 
Telomerase was detected in 15.5% of pathology positive tissue or adjacent to malignancy; in 
29.5% of pre-invasive cancer and in 84% of malignant cancer cells (Kim et al., 1994), 
whereas is undetectable in most normal somatic cells. Recent research found that the 
telomerase became detectable when the embryo had reached the 128 to 256-cell blastocyst 
stage (Wright et al., 1996).   
 
1.2.4 Telomerase complex 
 
1.2.4.1 hTERT 
 
Telomerase reverse transcriptase was first purified from Euplotes aediculatus termed as p123 
(Lingner et al., 1997). Almost simultaneously, the human catalytic subunit was identified by 
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four groups (Kilian et al., 1997; Meyerson et al., 1997; Nakamura et al., 1997; Harrington et 
al., 1997b). They found that the reverse transcriptase motifs are conserved among different 
organisms (Nakamura et al., 1997). Other recently study showed that the C terminus of 
hTERT possess more potential functions compared to the other organisms, and this 
specificity is believed to be the functions unique to higher eukaryotes (Banik et al., 2002).  
 
The hTERT gene had been previously mapped to the distal part of chromosome 5p15.33 
(Meyerson et al., 1997; Bryce et al., 2000). Human telomerase catalytic subunit encompasses 
over 35 kb, with 16 exons and 15 introns (Cong et al., 1999; Wick et al., 1999)(Fig 5).  
hTERT contains a telomerase-specific T motif and seven other motifs which are highly 
conserved in reverse transcriptase (Nakamura et al., 1997; Cong et al., 1999). The T motif 
locates very close to the N terminus of hTERT. Some research revealed that it has a critical 
role for the enzymatic activity and is responsible for the recognition of the hRT component 
(Lai et al., 2001). Sequencing analysis revealed that the hTERT promoter is GC-rich, 
contains several binding sites for different transcription factors (Cong et al. 1999), a notable 
one is myc binding site, which is known to induce hTERT expression (Wang et al., 1998). 
 
 
 
Fig 5. Localization of the exons and introns on the hTERT cDNA: 1, numbers in brackets indicate 
the extrons; solide cubes in turn indicate the T-motif and other seven motifs (Cong et al. 1999).     
 
An apparent correlation between the presence of hTERT mRNA and telomerase activity has 
been found (Meyerson et al., 1997; Ducrest et al., 2001). The human catalytic subunit was 
only detectable in various types of ovarian cancer cells, but not in normal, benign or low 
potential malignant (LPM) lesion of the ovary (Kyo et al., 1999). Based on these findings, 
inhibition of the expression of the catalytic subunit TERT has become a major target in 
anticancer drug development 
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1.2.4.2 hTR 
 
The RNA component (hTR) serves as a template for telomeric repeat synthesis. In human, 
hTR contains 451 nucleotides. The 11-basepair template sequence locates between 46 to 53, 
which is used for hybridization of the end of telomere (Feng et al., 1995). A secondary 
structure has been identified from different vertebrate species containing four conserved 
functional elements: CR2/CR3 domain; a CR4/CR5 domain; a box H/ACA domain and CR7 
domain (Mitchell et al., 1999; Dragon et al., 2000). The hTR box H/ACA motif has been 
shown to be essential for hTR accumulation, hTR 3’ processing, and telomerase activity in 
cells (Mitchell et al., 1999; Dragon et al., 2000; Dez et al., 2001), however, it is 
phylogenetically conserved among vertebrate telomerase RNAs (Chen et al., 2000) but not 
those of yeasts or ciliates, each of which appear to use a different strategy for accomplishing 
telomerase RNA accumulation in vivo (Seto et al., 1999; Aigner et al., 2000). It has been 
elucidated that the conserved domains within the hTR molecule are recognition sites for hTR 
binding proteins. A number of RNA binding proteins, such as hGAR, dyskerin, hNOP10, 
hNHP2, hStau, L22, hnRNP C1/C1, La, and hTERT, interact with hTR and are involved in 
hTR stability, maturation, accumulation, and functional assembly of the telomerase 
ribonucleoprotein complex (Mitchell et al., 1999; Dragon et al., 2000; Ford et al., 2000; Le 
et al., 2000; Ford et al., 2001; Cong et al., 2002). Two regions within the hTR molecule 
which locate at nucleotides from 1 to 209 and from 241 to 330 interact independently with 
the catalytic component hTERT (Mitchell and Collins, 2000). 
 
1.2.5  The regulation of telomerase  
 
It has been documented that among the core components of human telomerase complex, only 
the catalytic component hTERT seems to be the limiting determinant of telomerase activity. 
It is transcriptionally repressed in many normal cells and is reactivated or upregulated during 
immortalization. Whereas hTR is transcribed and accumulated in all human somatic cells and 
almost all human cell lines (Collins and Mitchell, 2002). The regulation of telomerase 
activity occurs at various levels, including transcription, mRNA splicing, maturation and 
modifications of hTR and hTERT, transport and subcellular localization of each component, 
assembly of active telomerase ribonucleoprotein, and accessibility and function of the 
telomerase ribonucleoprotein on telomeres (Collins and Mitchell, 2002).  
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1.2.5.1 Transcriptional regulation of hTERT 
 
A number of studies have showed that human telomerase is regulated during development 
and differentiation, mostly through transcriptional control of hTERT. Evidence showed that 
the expression of hTERT is a critical step during malignant transformation, the inactivity of 
telomerase is most frequently correlated with the absence of TERT mRNA (Meyerson et al., 
1997). Accordingly, the telomerase activity could be induced in normal cells after 
introducing the hTERT fragment by reporter gene assays (Bodnar et al. 1998; Vaziri and 
Benchimol, 1998). 
 
Several transcription factors have been identified as the candidate hTERT transcriptional 
activators, such as c-Myc, and Sp1. Some results have showed that the over-expressed c-Myc 
transcriptional factor could directly target hTERT gene through the canonical E-box elements 
(CACGTG), and induced its transcription (Horikawa et al., 1999; Wu et al., 1999; Oh et al., 
1999a). The hTERT promoter also contains binding sites for the zinc finger transcription 
factor Sp1 (Cong et al., 1999; Horikawa et al., 1999; Takakura et al., 1999). Sp1 could 
dramatically induce the hTERT promoter activity. The direct evidence was obtained by the 
EMSA analysis in several human cancer cells (Takakura et al., 1999). However, due to the 
fact that Sp1 is ubiquitous expressed in a wide range of normal cells, the protein by itself is 
unlikely to be a determinant of hTERT activator during carcinogenic processes (Horikawa 
and Barrett, 2003). Sp1 may interact with some other proteins to negatively regulate the 
hTERT transcription in normal cells, and to facilitate its function as an activator in cancer 
cells. 
 
A series research for the candidate hTERT transcriptional repressors was performed by Oh et 
al. The inhibitory effect on the hTERT promoter activity by the over-expressed WT1 was 
observed (Oh et al., 1999b). However, WT1 showed a restrict expression in specific tissues 
(kidneys, gonads and spleen) (Haber and Buckler, 1992) or cell lines (in 293 cells but not in 
HeLa cells) (Oh et al., 1999b) implying that the transcriptional repression of WT1 on hTERT 
is tissue-specific. Another identified hTERT transcriptional repressor was an E-box binding 
factor Mad1 (Oh et al., 2000), which competes with c-Myc for the common interacting 
partner Max and for the binding E-box element. Some tumor suppressor proteins or pathways 
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may regulate the hTERT transcription by acting through potential activator. For example, the 
TGF-β/Smad signaling pathway was known to down-regulate c-Myc expression (Chen et al., 
2001; Yagi et al., 2002). The activation or suppression of this pathway in human cancer cells 
led to a significant reduction or induction of hTERT expression and telomerase activity, 
respectively (Yang et al., 2001).  
 
It has been demonstrated that hTERT undergoes alternative splicing and several transcripts 
have been detected in human cells (Kilian et al., 1997). Two deletion sites and four insertion 
sites in hTERT mRNA were identified (Fig 6) (Kilian et al., 1997; Wick et al., 1999). With 
all these splicing sites are able to produce numerous combinations, till now only ten hTERT 
transcripts have been confirmed (Kilian et al., 1997; Hisatomi et al., 2003; Saeboe-Larssen, 
2006). The four insertions (indicated with numbers 1 – 4) cause premature translation 
termination, and two deletions (Fig. 7, as indicated as α and β) cause a 36-bp and 183-pb loss, 
respectively. Within all of the transcripts are expressed only the full-length hTERT transcript 
is associated with telomerase activity (Ulaner et al., 1998), whereas the α variant was 
clarified as a dominant negative inhibitor of telomerase activity (Colgin et al., 2000; Yi et al., 
2000), and the β deletion played a negative regulatory role on telomerase activity (Lincz et 
al., 2008).  
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Fig 6.  Gene structure of hTERT. A: four insertions and two deletions are indicated with either 
numbers 1 - 4 or letters α and β. B: Different transcripts generated through alternative splicing. 
Insertions are not indicated in this figure. Two deletions produce four possible combinations of 
hTERT alternative splice variants (Yi et al., 2000).   
 
1.2.6 Telomeres and telomerase as targets for anticancer drug development 
 
Cancer is a group of diseases characterized by infinite cell growth and spread of abnormal 
cells. Cancerous development has been elucidated as a multi-step process with dynamic 
alternations in the genome (Hanahan and Weinberg, 2000), these alternations are 
accumulated and eventually drive a progressive transformation of normal cells into a 
malignant state.  
 
Targeting telomerase: Based on the evidence that over 85% human cancer cells express 
telomerase activity (Kim et al., 1994), the cancer-associated specificity makes telomerase a 
superb target for the diagnosis of malignancy and for the development of novel anticancer 
drugs. Some research has demonstrated that several chemical compounds, like 2-((E)-3-
naphtalen-2-yl-but-2-enolylamino)-benzonic acid (BIBR1532) (Damm et al., 2001) or the 
similar compound 2,3,7-trichloro-5-nitroquinoxaline (TNQX) (Kim et al., 2003), inhibit 
                                                                                                                                  Introduction 
                                                                                                                                                  23                                                                                                                                                      
telomerase activity, lead to a remarkable cell cycle arrest and initiate apoptosis (Hahn et al., 
1999; Damm et al., 2001; Ahmed and Tollefsbol, 2003) and/or premature senescence 
(Bodnar et al. 1998; Damm et al. 2001; Gewirtz et al. 2008). More and more reports show 
that targeting telomerase is a valid strategy to combat cancer. However, since telomerase 
activity could also be detected in germline cells and embryonic cells (Mantell and Greider, 
1994), so it seems these normal cells would loose their proliferative capacity during the 
treatment. Another problem also limits the telomerase-inhibitor usage, the lag period. The lag 
period highly depends on the initial telomere length in cancer cells, which may require a 
rather long time to approach critical shortening of telomeres to induce cell cycle arrest (Hahn 
et al., 1999).  
 
Targeting telomeres: Beside targeting telomerase, the telomeric repeat itself is also a 
substrate for anticancer agents. As we described earlier, the G-rich single stranded overhang 
is able to fold back on itself in vitro to form a special G-quadruplex structures. However, the 
structure of human telomere in vivo is not fully determined, and it remains unclear whether 
the end of chromosome ends actually form T-loop, G-quadruplexes, or other structures in 
vivo. Nevertheless, in principle, small molecules are able to stabilize the G-quadruplex 
structures, presumably by intercalation, and whereby block the access of telomerase during 
the elongation step (Zahler et al., 1991; Parkinson et al., 2002). To date, a number of G-
quadruplex stabilizing ligands have been discovered and tested ever sine the first molecule, 
2,6 diamidoanthraquinone was identified (Sun et al., 1997). These G-quadruplex-associated 
ligands include TMPyP4 (Shi et al., 2001), triazines (12459) (Riou et al., 2002), anionic 
porphyrins (NMM) (Arthanari et al., 1998) and a natural product telomestatin (Shin-ya et al., 
2001). However, in contrast to telomerase, telomeres are present in normal cells as well as in 
cancer cells, so the risk of cytotoxicity is another issue to overcome for the future agent 
development.  
 
1.3 CELLULAR SENESCENCE 
 
1.3.1 Introduction 
 
Cellular senescence was originally defined by Hayflick in the early of 1960s (Hayflick, 1965). 
In his research, he observed that human diploid cell strains, especially fibroblast cells, cease 
dividing after a certain number of doublings. Via two experiments, he concluded that the 
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reason why cells stopped dividing was neither the external factor, nor the cumulative period 
of cell freezing (Larsson, 2005). Thus, he firstly named the phenomenon phase III and later 
on it was called Hayflick limit, cellular senescence or replicative senescence. The latter two 
are commonly used in present study. Hayflick’s remarkable finding opened up a way to 
understand, in opposite to normal cell, how cancer cells remain immortal, and therefore, to 
give the modern research a hint for effective treatments for cancers (Shay and Roninson, 
2004).    
 
1.3.2 Replicative senescence 
 
1.3.2.1 The senescent phenotype 
 
Replicative senescence is defined by a set of phenotypic changes including cellular arrest, 
and the altered morphology. Senescent cells cease dividing but remain metabolically active 
and produce many secreted factors. The cellular arrest of proliferation accompanied by 
changes in cell function, such as changes in secretory pathways, expression of protease, 
extracellular matrix components and inflammatory cytokines (Cristofalo et al., 2004; Shay 
and Wright, 2005). Senescent cells display a gradual loss of proliferative potential which 
results in a reduction in cell density (Cristofalo, 1988) and leads to an irreversible growth 
arrest. However, some research groups have argued that the irreversible status is actually 
reversible. Recent data has showed that the senescent mouse embryonic fibroblasts (MEFs) 
could be reversed when p53 expression was inhibited through RNA interference, and such 
suppression of p53 in senescent MEFs caused a rapid cell cycle re-entry and led to 
immortalization (Dirac and Bernards, 2003). The senescent cell is mainly characterized by a 
number of changes in morphology, including cellular enlargement and flattening, the 
increase in the size of nucleus and nucleoli (Cristofalo and Kritchevsky, 1969; Mitsui and 
Schneider, 1976; Greenberg et al., 1977) as well as an increase of lysosomes and Golgi 
(Alvaro et al., 1971; Cristofalo and Kabakjian, 1975). Moreover, the populations of 
senescent cells reveal an increased number of multinucleated cells (Yanishevsky and Carrano, 
1975; Galloway and Buckton, 1978). In addition to the morphological changes, Zhang et al 
has reported that the global changes in gene transcription occurring during replicative 
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senescence in human fibroblasts and mammary epithelial cells (HMECs), the gene 
expression perturbations during senescence differ greatly in fibroblasts and HMECs. 
1.3.2.2 What drives replicative senescence? 
 
Although a commonly accepted theory has been established, in which the progressively 
shortened telomeres initiate replicative senescence (Wright and Shay, 1992; Bodnar et al., 
1998), as Shay described in his review there still remain some uncertainties about the actual 
inducing events that ‘trigger’ senescence (Shay and Wright, 2005). 
 
1.3.2.2.1 The theory of replicative senescence 
 
Telomeres are G-rich structures located at the end of each chromosome. It consists of tandem 
DNA sequence TTAGGG and associated proteins , such as TRF1, TRF2, TIN2, TPP1, and 
POT-1, etc, these proteins remain in a complex with telomeric DNA (fig 3) throughout the 
cell cycle (de Lange, 2005) (More related details have been shown in chapter 2). In normal 
cells, the progressive telomere shortening occurs alongside each cell division (Allsopp et al., 
1995), after a certain number of division, the telomere approaches a critical length, thus, cells 
stop dividing and enter replicative senescence. The number of cell divisions can be different 
according to the species, age and genetic background of the donor, the number can be fairly 
large, for example, 60-80 doublings in some cases (Campisi, 1997). The senescent cells 
cannot be stimulated to enter the S phase of the cell cycle by any known combination of 
physiological mitogens. The direct evidences were obtained from in vivo and in vitro show 
that the extreme shortened telomeres trigger replicative senescence (Smith and Pereira-Smith, 
1996; Bodnar et al., 1998; Morales et al., 1999). When the hTERT catalytic subunit was 
introduced to senescent cells, the cells could bypass senescence and became immortal with 
ongoing cell division. There are two hypotheses to explain this phenomenon. Firstly, during 
telomere shortening, the proteins that usually form a complex together with telomeres are no 
longer able to locate due to the length of the telomere, which consequently initiates a DNA 
damage response and eventually general senescence (van Steensel et al., 1998; Blackburn, 
2000;2001). Secondly, the sequence or the structure of telomere is compromised, which does 
not particularly imply to the double stranded telomere, but the single stranded telomere. 
Evidence showed that the loss of 3’ G-rich overhangs triggers senescence, 60-85% of the 3’ 
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overhangs are eroded during senescence (Stewart et al., 2003). However, in contrast with this 
result, Chai et al has reported that no loss of single stranded overhang was detected in their 
research. Results obtained from the conventional nondenaturing hybridization assay showed 
that the normal human fibroblasts could maintain their overhangs at senescence (Chai et al., 
2005).  
 
1.3.2.2.2 Signaling of replicative senescence 
 
Replicative senescence can be initiated in various cell types through different pathways. The 
most commonly described in ration to senescence are the p16/Rb pathway and the p53/p21 
pathway. In this study, we particularly focus our attention on the latter.  
 
The finding has been documented from different groups that replicative senescence is 
correlated to DNA damage response (Shay and Roninson, 2004; Zhang et al., 2005). 
Telomeres in senescent cells have typical DNA damage foci, which include nuclear foci of 
phosphorylated histone H2AX (γH2AX) and its co-localization with DNA repair and DNA 
damage checkpoint factors such as 53BP1 (Wang et al., 2002), MDC1 (Goldberg et al., 2003) 
and NBS1 (di Fagagna, 2003; Sedelnikova et al., 2004). γH2AX has gained much attention 
for its relationship with DNA damage, particularly double strand breaks (DSBs) (Redon et al., 
2002; Pilch et al., 2003). The phosphorylated γH2AX forms localized “foci” at the sites of 
DSBs (Rogakou et al., 1998; Paull et al., 2000) and it is dependent on signaling pathways 
involving p53, p21WAF1/CIP1 but not p16INK4a (Herbig et al., 2004).  
 
p53 encoded by the tumor suppressor gene has been reported to act as an integrator of 
various cellular events, such as cell cycle arrest, apoptosis, differentiation, and lately 
described senescence. The in vitro result suggested that p53 is the most noticeable regulator 
in cellular senescence (Sugrue et al., 1997). p53 is presumed having potential roles for 
recognizing dysfunctional telomeres and maintaining telomere complex integrity due to the 
observation that p53 binds to the single stranded telomeric overhangs, and thereby, 
cooperates with TRF2 in the formation of the T-loop (Stansel et al., 2002). Although it has 
been investigated that the senescence response to telomere dysfunction is reversible and is 
maintained primarily by p53 (Beausejour et al., 2003), the precise roles of this process are 
not fully understood. p53 is postulated to treat dysfunctional telomeres as damaged DNA, 
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which in turn activates p53. p53 can be activated through different signals, some of them via 
post-translational modification like acetylation or phosphorylation (Shieh et al., 1997; 
Kapoor and Lozano, 1998; Sakaguchi et al., 1998; Webley et al., 2000). The p53 gene 
performs a critical regulation in the cell cycle (Levine, 1997; Gire and Wynford-Thomas, 
1998), when a genotoxic stress occurs, the increased level of p53 protein stops the cell cycle 
either at G1 or G2 (Levine, 1997). Cell growth arrest in senescence is tightly associated with 
switching on the transcriptional function of p53, which was assessed by using reporter 
constructs and by DNA binding assays (Bond et al., 1996). A role of p53 in replicative 
senescence emerged lately (Gewirtz et al., 2008), and was enforced by the observation that 
both antisense p53 and papillomavirus protein E6, which mediates p53 degradation, lead to 
an extension of life span in human diploid fibroblasts (Scheffner et al., 1990; Hara et al., 
1991; Shay et al., 1991).  
 
Table 3. Induction of cell fate in human cancer cells following chemotherapy or radiation 
(Gewirtz et al,. 2008) 
Table 1 – Induction of cell fate in human cancer cells following chemotherapy or radiation 
  Cell line               p53 status          Modality                                          Cell fate  
 
  
     MCF-7                          +                            AdR                                                                 Senescence + MCa 
                                           +                            SN-38, IR                                                        Senescence  
     MCF-7 hTERT             +                            AdR                                                                Senescence  
     MCF-7 HPV-16 E6       -                            AdR                                                                 Apoptosis >> senescence  
                                            -                            IR                                                                    Apoptosis >> senescence  
     MDA-MB231               -                             AdR                                                                Apoptosis >> senescence  
                                            -                            IR                                                                    Apoptosis >> senescence 
     HCT116                        +                            AdR                                                                Senescence + MC  
                                           +                            VP-16, SN-38, camptothecin, cisplatin          Senescence 
     HCT116 p53-/-              -                            AdR, VP-16                                                    Apoptosis + MC >> senescence  
                                            -                            SN-38, cisplatin                                              Apoptosis >> senescence  
                                            -                            Camptothecin                                                  Apoptosis  
     HCT116 p21-/-             +                            AdR, VP-16, SN-38, IR, Camptothecin         Apoptosis                                                                                                     
                                           +                            Cisplatin                                                         Apoptosis >> senescence  
     H1299                            -                            VP-16                                                              Senescence  
                                            -                             IR                                                                   Apoptosis  
     H1299 + p53                 +                            IR                                                                    Senescence  
     Glioblastoma                 +                            SN-38, IR                                                       Senescence  
     Glioblastoma p53-/-      -                             IR                                                                    Apoptosis 
 
a MC: mitotic catastrophe. 
 
Once activated, p53 induces many other transcriptional factors involved in cell cycle arrest or 
apoptosis (Giaccia and Kastan, 1998; Zhao et al., 2000), one of them is p21. p21 is a cyclin-
dependent kinase (CDK) inhibitor, which inhibits CDK activity throughout all phases of cell 
cycle by directly binding with multiple cyclins and CDKs and, therefore, inhibiting CDK 
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activity in vivo and in vitro (Harper et al., 1993; Xiong et al., 1993). The growth arrest which 
is caused by p53 is believed to occur through transcriptional activation of the cyclin-
dependent kinase inhibitor p21 (fig 7) (Eldeiry et al., 1993; Harper et al., 1993; Agarwal et 
al., 1995). During p53-dependent cell proliferation repression, p21 is important for 
coordinating cell cycle progression, DNA replication, and repair of damaged DNA. Recent 
studies have suggested that p21 mainly inhibits CDK2/cyclin-E (Sherr and McCormick, 2002) 
and lesser effect on CDK4/cyclin-D (Giaccia and Kastan, 1998). Although it was predicted 
that p21 inhibits Cdk2 activity by a similar mechanism of p27 (Zhu et al., 2005), in which 
p27 inhibits CDKs by inserting into the catalytic cleft (Jeffrey et al., 1995), the actual 
interactive pattern between p21 and Cdk2 remains unclear. In telomere-associated senescence, 
p53 activates p21 gene expression in response to DNA-damaging stress, and the increased 
level of p21 protein then binds CDKs complexes, resulting in cell cycle arrest (Brugarolas et 
al., 1995; Deng et al., 1995). An important role of p21 for the induction of senescence in 
human cells has been revealed from different researches. Some data showed that p21 was 
able to induce senescence in a p53-independent manner (Fang et al., 1999; Wang et al., 
1999); and the other result showed that p21-deficient human fibroblast cells could bypass 
senescence (Brown et al., 1997; Wei et al., 2001).  
 
 
 
             Fig 7. Induction of senescence in normal cells (Shay and Roninson, 2004).  
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1.3.3 Premature senescence 
 
In addition to replicative senescence which is caused by the progressive telomere shortening, 
growing evidence showed that telomere dysfunction leads to an “uncapping” situation by 
several stimuli in normal and malignant cells (Serrano et al., 1997; Robles and Adami, 1998; 
Serrano and Blasco, 2001; Ramirez et al., 2003), such stimuli include UV- and γ-irradiation 
(Gorbunova et al., 2002), transformaing growth factor (TGF-β) (Katakura et al., 1999; 
Untergasser et al., 2003), hydrogen peroxide (Duan et al., 2005) and some chemotherapeutic 
agents (Chang et al., 1999a; Christov et al., 2003). Many anticancer agents induce apoptotic 
cell death through activating DNA damage signaling pathways. However, it was lately 
argued that in some cases cells do not die but instead undergo a senescence-like cell cycle 
arrest (Chang et al., 1999b; Elmore et al., 2002; Zhao et al., 2004). Mounted data suggest 
that such cellular stimuli can initiate the change of telomeric DNA structure or sequence 
(Crabbe et al., 2004), mutation of telomere-associated proteins (Machwe et al., 2004; Yang 
et al., 2005), which in turn trigger premature senescence (Serrano et al., 1997; Robles and 
Adami, 1998; Naka et al., 2004; Shay and Roninson, 2004). Furthermore, the uncapped state 
leads to a rapid cell cycle arrest, at the meantime accompanied with many of the same 
morphological and biochemical features for replicative senescence. The growth arrest which 
is caused by cellular stimuli is in fact similar to replicative senescence, and also fails to react 
to mitogens stimulation. Moreover, premature senescent cells also remain metabolic and 
synthetic activity (Serrano et al., 1997; Drayton and Peters, 2002; Shay and Roninson, 2004).  
 
The response of cells to replicative senescence versus premature senescence may or may not 
be similar, but in both cases, the compromising of telomere function leads to cell growth 
arrest or cell death, and a common possibility, DNA damage response, may be involved in 
both issues.   
 
1.3.4 Cellular senescence and cancer 
 
Shay and Campisi have pointed out that, at least in human cells, replicative senescence is a 
powerful tumour suppressive mechanism (Campisi, 1997; Shay and Roninson, 2004).  
 
An important distinction among all kinds of organisms is to have renewable tissues that are 
essential for viability, and these renewable tissues have evolutionarily conserved defense 
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mechanisms that guard against unrestrained proliferation (Campisi, 2003; Shay and Roninson, 
2004). A progressive accumulation of damage must take place alongside the cell division; 
such damage can be generated through epigenetic or genetic pathway. Cancer cells must 
accumulate many mutations before acquiring malignant characteristics. Therefore, limiting 
the number of available cell divisions would prevent pre-malignant cells from dividing after 
accumulating only a few mutations, and thus block their progression (Campisi, 2003; Shay 
and Roninson, 2004).  
 
Cellular senescence is also believed,  at least among vertebrates, to be a evolutionary 
conserved process (Campisi, 2003). The senescence phenotype combined with cell growth 
arrest were observed in different species under certain conditions (Campisi, 2001). Moreover, 
senescence was also identified in non-telomere associated cases (Margolis and Spradling, 
1995; Jazwinski, 1996). People found that Yeast or Drosophila ovarian stem cells could also 
undergo senescence after several times of division, but no telomere shortening was observed 
in senescent cells.  
 
Evidence showed that most cell lines are senescence inducible in counteracting some 
chemotherapy treatment (Chang et al., 1999a) and this result was confirmed by the in vivo 
response to chemotherapy in mice (Chang et al., 1999a; Schmitt et al., 2002). It was 
speculated that cancer cells acquire mutations through several common signaling pathways 
(Yeager, 1998; Hanahan and Weinberg, 2000), these mutations tend to inactivate either the 
p53 or RB pathways or their upstream positive regulators, which in turn prevent the 
senescence response. This hypothesis was afterwards confirmed from different groups. When 
manipulating the expression of p53 and Rb in vitro, it causes cells either to ignore 
senescence-inducing signals (Hara et al., 1991; Shay et al., 1991; Gire and Wynford-Thomas, 
1998) or to arrest growth with a senescent phenotype (Sugrue et al., 1997; Bringold and 
Serrano, 2000; Lundberg et al., 2000; Itahana, 2001). However, the senescence-promoting 
and senescence-suppressing factors in cancer cells exist in a dynamic equivalent pattern, 
which can be shifted in favor of senescence by a variety of cellular stimuli, and thereby to 
inhibit cancer cells growth (Bertram et al., 1999; Goodwin et al., 2000; Wells et al., 2000). 
Taken together, the enhancement of the program of senescence in cancer cells provides a 
biologically approach to cancer therapy.     
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1.4 AIM OF THE WORK 
 
Plants produce plenty of secondary metabolites (SM), the alkaloids are one of the most 
diverse groups of SM found in living organisms and have a series of structure type. Many 
alkaloids have been identified possessing strong toxic properties towards animals and human. 
During the past decades, more attention has been drawn on their anticancer potencies. A 
number of alkaloids have been used as anticancer drug over 40 years.  
 
In this study, three alkaloids harmine, emetine, and sanguinarine were selected. Data 
obtained from in vitro studies showed that these alkaloids commonly interact with DNA, 
preferentially with G-quadruplexes in a manner of intercalation. Human telomere has been 
characterized able to form two types of G-quadruplex. However, little direct evidence of in 
vivo study is available so far. Therefore, we introduced these compounds into different 
human cancer cells in order to determine their anti-cancer properties and to investigate the 
effect on human telomerase and the associated pathways. We particularly focused our 
attention on the alkaloid harmine.  
 
The aim of this work can be summarized as 
 
1. To determine the anti-proliferative and cytotoxic properties of harmine, emetine, and 
sanguinarine in human breast cancer MCF-7 cell line and human cervical cancer 
HeLa, and SiHa cell lines.  
2. To investigate the inhibitory effect of harmine, emetine, and sanguinarine on human 
telomerase. 
3. To investigate and clarify the potential pathway in MCF-7 and HeLa cells after the 
treatment of harmine. 
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2 MATERIAL AND METHODS 
 
2.1 CELLS 
 
In order to carry out this project, three different carcinoma cell lines- HeLa, SiHa and MCF-
7- were used.  Hela and SiHa cells are human cervical cancer cells. HeLa cells were routinely 
cultured in our lab; SiHa cells were kindly offered by Dr. Thomas Hofmann (German Cancer 
Research Center, DKFZ). MCF-7 is human breast adenocarcinoma cell line which was 
kindly provided by Prof. Dr. Stefan Wölfl.  
 
 2.2 INSTRUMENTS 
 
Instrument Company 
Centrifuge Hermle ZK 364  M & S Laborgeraete GmbH, Wiesloch 
Centrifuge J2-21, Rotor JA-14 Beckmann, Muenchen 
Centrifuge Megafuge 1.0R Heraeus Sepatech, Wiesloch 
CO2 incubator B5060 EK/CO2 W. C. Heraeus GmbH, Hanau 
Experion™ automated electrophoresis station Biorad, Muenchen, Germany 
Experion™ priming station Biorad, Muenchen, Germany 
Experion™ vortex station Biorad, Muenchen, Germany 
High pressure steriliser CertoClav KELOmat – Sterilizer Division, Australia 
Hoefer TM SE600 Electrophoresis chamber Amersham Biosciences, Freiburg 
LightCycler Instrument Roche Biosciences GmbH, Penzberg 
Lightmicroscope Nikon Cooperation, Tokyo, Japan 
Liquid Nitrogen Liquide GT35 AIR LIQUIDE GmbH, Duesseldorf 
Microplate reader Tecan Safire2, Crailsheim, Germany 
Multistep - Pipette Eppendorf Deutschland GmbH, 
Wesseling-Benzdorf 
NanoDrop 2000 Thermo Fisher Scientific Inc, USA 
Neubauer chamber Neolab®, Heidelberg 
Thermocycler Biometra GmbH, Goettingen 
Pipette Eppendorf Deutschland GmbH, 
Wesseling-Benzdorf 
Pipettus® KG, Eberstadt 
Precisionbalance Sartorius Basic Sartorius AG, Goettingen 
Spectrophotometer  Eppendorf 
UV – Transilluminator Biogene 6.02 processing system 
Heidolph Instruments GmbH & Co.KG, 
Vortex Heidolph Relax top Schwabach 
Waterbath Julabo P Julabo Labortechnik GmbH, Seelbach 
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2.3 LABORATORY MATERIALS 
 
Material Company  
Cellculture flasks Cellstar® 25 cm2 Greiner bio-one GmbH, Frickenhausen 
Cellculture plates Cellstar®  
(96-well, 24-well, 6-well) 
Greiner bio-one GmbH, Frickenhausen 
Cryotubes  Greiner bio-one GmbH, Frickenhausen 
Distritip multi step syringe  
(Gilson 12.5 ml, 1.25 ml) 
Abimed, Langenfeld 
Eppendorf safe lock reaction tubes 
(2 ml, 1.5 ml, 0.2 ml, 0.1 ml) 
Eppendorf AG, Hamburg 
MultiGuard™ Barrier Tips 
(10 µl, 100 µl, 1000 µl) 
Sorenson BioScience, Inc 
LightCycler capillaries Roche diagnostics GmbH, Penzberg 
Syringe Driven Filter Unit  
(0.22 µm, 0.45 µm) 
Millipore Corporation, U.S.A  
Pipettes  
(serological, sterile, 5 ml, 10 ml, 25ml) 
Greiner bio-one GmbH, Frickenhausen 
Steritop™ & Stericup® , 500 ml Millipore Corporation, U.S.A 
  
 
2.4 KITS 
 
Kit  Company  
Absolute ™ QPCR SYBR® green capillary 
mixes Abgene House, Surrey, UK 
RNeasy Mini kit QIAGEN, Hilden, Germany 
RNase-free DNA set QIAGEN, Hilden, Germany 
ImProm-II™ Reverse Transcription System Promega, Corporation, Madison, USA 
Taq polymerase Bioron GmbH, Ludwigshafen 
SuperSignal West Dura Extended Duration 
Substrate Thermo Scientific, 
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2.5 BUFFER AND SOLUTION 
  
All solutions and buffers were made in sterilized water, if not otherwise indicated. 
 
Phosphate Buffered Saline (PBS) 
 
NaCl                                                                    140 mM 
KCl                                                                      13.4 mM 
Na2HP4                                                                0.007 mM 
HCl                                                                      adjust to pH 7.4 
 
Lysis buffer for TRAP assay (DEPC water) 
 
Tris-HCl, pH 7.5                                                 10 mM 
MgCl2                                                                  1 mM 
EGTA                                                                  1 mM 
CHAPS                                                                0.5% 
Glycerol                                                               10% 
 
10 × TRAP buffer (made in DEPC water) 
 
Tris-HCl, pH 8.3                                                  200 mM 
MgCl2                                                                  15 mM 
KCl                                                                       680 mM 
Tween 20                                                              0.5 % 
 
12.5% Arcylamide Gel solution (400 ml) 
 
40% Acrylamide (19:1)                                      125 ml 
5 × TBE buffer                                                    40 ml 
ddH2O                                                                 235 ml 
 
PAGE/0.5 × TBE gel (40 ml) 
 
12.5% Acrylamide solution                                12.5 ml 
10% APS                                                             400 µl 
TEMED                                                               40 µl 
5 × TBE buffer                                                    27.5 ml               
 
5 × TBE buffer (pH 8.3) 
 
Tris Base                                                             445 mM 
Boric Acid                                                           445 mM 
EDTA (pH 8.0)                                                   10 mM 
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Cell Fixative solution (made in PBS)  
 
2% (v/v) Formaldehyde  
0.2% (w/v) Glutaraldehyde 
 
PI staining solution (made in PBS) 
 
PI                                                                       50 µg/ml 
RNase                                                                0.1 mg/ml 
Triton X-100                                                     0.05% 
 
X-Gal stock solution (10 ml) 
 
X-Gal                                                                 200 mg 
DMF                                                                  10 ml 
Store at -20 ºC in aliquots                               
 
SA-β-Galactosidase staining solution  
 
K3[Fe(CN)6]                                                       5 mM 
K4[Fe(CN)6]                                                       5 mM  
MgCl2                                                                 2 mM 
NaCl                                                                   150 mM 
Citric acid/PBS, pH 6.0                                      40 mM 
X-Gal                                                                 1mg/ml (add freshly) 
 
NP40 Buffer (for Western Blot) 
 
Tris HCl pH 7.4                                                  20 mM 
NaCl                                                                   150 mM 
EDTA                                                                 5 mM 
NaF                                                                     25 mM 
NP40                                                                  1% 
Glycerol                                                             10% 
 
Bradford reagent 
 
Coomassie Brilliant Blue G-250                        100 mg 
95% Ethanol                                                       50 ml 
85% (w/v) Phosphoric acid                                100 ml 
 
Dilute into 1 liter of distilled water when the dye has completely dissolved and filter with 
Whatman paper 
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SDS – PAGE (12%) 
 
Acrylamide mix                                                   40% 
Tris-HCl pH 8.8 (1.5 M)                                      375 mM 
SDS                                                                       0.10% 
APS                                                                       0.10% 
TEMED                                                                 0.04% 
 
2 × Sample buffer 
 
Tris-HCl, pH 6.8                                                   130 mM 
SDS                                                                       6% 
Glycerol                                                                20% 
β-mercaptoethanol                                                10% 
Bromophenol blue                                                0.1% 
 
Running buffer            
 
Glycin                                                                   194 mM 
SDS                                                                       0.1% 
Tris                                                                        33 mM    
 
TAE buffer 
 
Tris                                                                         40 mM 
EDTA                                                                    1 mM 
Acetic acid                                                             adjust to pH 8.8 
 
Transfer buffer  
 
Tris-base                                                                33 mM 
Glycine                                                                  192 mM 
Methanol                                                                20% 
 
Blocking buffer (made in TBS-T buffer) 
 
Non-fat-milk                                                           5% 
Tween20                                                                 0.05% 
 
Store at 4 ºC to avoid bacteria contamination 
 
10 × TBS-T buffer 
 
Tris, pH 8.0                                                            100 mM 
NaCl                                                                       1.5 M 
Tween20                                                                 0.1% (as final concentration v/v) 
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3. METHODS  
 
3.1 Cell culture 
 
3.1.1 Maintenance of cell cultures 
 
All media and solutions which were required in cell culture are listed in table 3. Cells were 
cultured in DMEM medium containing 10% FBS, 1% 20 mM glutamine, cells were 
incubated at 37 ºC of 5% CO2 and passaged every 3 or 4 days. During cell subculture, 
medium was discarded and 3 ml trypsin/EDTA solution was added into 75-ml flask, returned 
the flask back to the incubator and incubated for about 3 min. The digestion was stopped by 
adding 5 ml fresh cell culture medium, the cell solution was pipetted up and down several 
times in order to separate the cell clumps into single cells, and then ¼ volume of the cell 
suspension was kept culturing by adding another certain amount of fresh medium. Cell 
culture medium was replaced during cell culturing only if necessarily.   
   
3.1.2 Cell cryopreservation 
 
To prepare frozen stock cultures, cells were harvested and the cell suspension was 
centrifuged at 2000 rpm for 10 min. The cell pellet was then resuspended in pre-cooled fresh 
culture medium containing 10% FBS and 10% DMSO, pipetted gently up and down to 
separate cell clumps. The density of cell solution was conducted in a counting chamber, and 
then about 1 × 106 cells were transferred into Cryo-tubes. Cell cryopreservation was 
performed by the protocol that cell solution was kept at 4 ºC for 30 min and – 20 ºC for 2 h, 
then the frozen cells were stored in liquid nitrogen. 
 
             Table 4. Media and solutions for cell culture  
 
                  Cell culture media and solution 
DMEM Dulbeccos’s Modified Eagle’s Medium 
(Invitrogen, USA) 
FBS Heat-inactived at 56 ºC 30 min (PAA 
Laboratories GmbH, Germany)  
Freezing medium DMEM containing 20% FBS, 8% DMSO 
Trypsin/EDTA 0.5% trypsin/EDTA 
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3.2 CELL CYTOTOXICITY ASSAY (MTT ASSAY) 
 
In this study, the MTT assay was taken to assess the cytotoxicity of alkaloids on human 
cancer cell proliferation. MTT assay was first described by Mosmann (Mosmann, 1983). The 
method is based on the ability of a mitochondrial dehydrogenase from viable cells to cleave 
the tetrazolium rings of the pale yellow MTT, and form purple formazan crystals which are 
impermeable to cell membranes. The crystals can be solubilized by detergents. The number 
of living cells is directly proportional to the level of the formed formazan, which can be 
quantified photometrically.  
 
3.2.1 Cell Preparation 
 
Cells were placed into 96-well plates and incubated at 37 ºC overnight; cells were then 
treated with alkaloids in various concentrations. Each concentration was repeated in triplicate 
manner. Medium with or without compounds was replaced every 24 hours with fresh 
medium containing the same concentrations of compounds. Cells were then grown in the 
continuous presence of drugs up to different time points (24 h, 48 h, 72 h and 96 h). After 
treatment, cells were collected for either cytotoxicity assay or cell proliferation assay. The 
experiments were repeated three times independently. 
 
3.2.2 Preparation of harmine, emetine and sanguinarine stock solutions 
 
Harmine (C13H12N2O; MW 212.25), emetine (C29H40N2O4; MW 480.65) and sanguinarine 
(C20H14NO4; MW 332.34) were purchased from Sigma Aldrich Company. These compounds 
were dissolved either in DMSO or in water according to the user instruction, respectively. All 
stock solutions were prepared as stock concentration of 100 mM, and stored at -20 ºC. The 
pH values of these solutions were determined after mixing with DMEM medium, each of 
them displayed the pH value between 7 and 8. 
 
3.2.3 Absorbance measurement  
 
After the treatment with alkaloids, the cell culture medium was removed gently, MTT stock 
solution was added to a final concentration of 0.5 µg/ml, and incubated at 37 ºC for about 2 
to 4 hours until the purple formazan crystals had formed clearly. The MTT solution was 
discarded carefully, formazan crystal was dissolved in 100 µl DMSO containing 10% SDS 
and 1% acetic acid. The plates were mounted on top of a shaker and were shaken for 10 min 
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until the formazan crystals were dissolved completely, the concentration was determined at 
an optical density at 570 nm in Safire2 Microplate reader. Experiments were repeated three 
times independently.    
 
3.3 TELOMERASE ACTIVITY ASSAY  
 
The polymerase chain reaction (PCR) based telomeric repeat amplification protocol (TRAP) 
was originally developed by Kim et al (Kim, Piatyszek et al., 1994). It is applied specifically 
to detect telomerase activity.  
Principle (Fig 7): the assay measures enzymatic activity of telomerase. The TS primer acts 
as a substrate for telomerase-mediated addition of TTAGGG repeats. Addition of the repeats 
occurs at 25ºC, after which PCR is used to amplify the extended products. The TS primer 
serves as forward primer while CX is the reverse primer for PCR. The products are then 
separated by electrophoresis on a 12.5% polyacrylamide gel, which is then stained with 
Sybergreen (Molecular Probes) to visualize the 6 bp ladder. TS primer: AAT CCG TCG 
AGC AGA GTT, CX primer: CCC TTA CCC TTA CCC TTA CCC TAA. 0.5 µg protein 
extract is analyzed for each sample. An internal control (IC) is included in TRAP assay, 
which denotes a 36-bp band that serves to normalize sample to sample variation. IC is 
unrelated to telomerase activity and is not included in the protein quantitation. 
 
 
         Fig 8. TRAP assay protocol (Kim, Piatyszek et al., 1994). 
 
 
3.3.1 Protein extract preparation and quantitation for TRAP assay  
 
Cell samples were prepared in 24 well plates and exposed to different compounds, and then 
the protein extracts were prepared. The cell culture medium was removed and the cells were 
washed twice in pre-cooled PBS, then the plates were placed on ice and 100 µl of CHAPS 
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lysis buffer was directly added into each well. The cell lysate was pipetted up and down 
every 10 min with nuclease-free tips in order to ensure cells were lysed completely, and then 
centrifuged 12,000 rpm for 30 min at 4 ºC, the supernatants were then transferred into new 
DEPC treated Eppendorf tubes. The protein concentrations were determined by Bradford 
assay. In acidic environment, protein binds to coomassie dye, which induces a spectral shift 
from brown form of the dye. The difference between these two forms is greatest at 595 nm, 
so it is taken as optimal wavelength for protein-coomassie dye complex measurement. A 
standard curve was developed by a series of BSA solution in increased concentrations, 
ranging from 2.5 to 20 µg/ml. The measurement was conducted by spectrophotometry at 595 
nm. All steps were carried out on ice in order to avoid protein degradation.  
 
3.3.2 Telomeric Repeat Amplification Protocol (TRAP) 
 
TRAP reaction was performed according to the protocol of Kim et al (Kim, Piatyszek et al., 
1994). All solutions and buffers were self-made and prepared in DEPC water. 0.5 µg of cell 
extract was analyzed. CHAPS lysis buffer was included as negative control. 
 
3.3.3 The separation of TRAP productions and quantitation of telomerase activity  
 
TRAP products were separated in non-denaturing 12.5% acrylamide gels. The gels were 
stained in SYBR green containing solution and visualized under UV – Transilluminator. The 
intensity of each ladder was then detected and calculated by the software ImageJ (National 
Institutes of Health, Maryland). The relative telomerase activity (RTA) was conducted by 
taking the values to the formula (Betts and King, 1999):  
 
                                  (s-b)/ ics 
              RTA =                               ×100 
                                 (pc-b)/icpc                       
 
The values are expressed as % of the control sample. 
 
3.4 REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ( RT- PCR ) 
AND RELATIVE QUANTIFICATION-POLYMERASE CHAIN REACTION 
( Real- Time PCR ) 
 
 
s: Intensity of sample 
pc: Intensity of positive control 
b: Intensity of background 
ic: Intensity of internal control 
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3.4.1 Total RNA isolation, qualification and quantitation 
 
Cell samples were prepared in 6 well plates. After a certain time of treatment, the total RNA 
was isolated by using RNeasy Mini-Kit (QIAGEN) according to the manufacture’s 
instruction. The RNA pellets were then dissolved in nuclease-free water and stored at -80 ºC 
until use. The concentrations were determined by a NanoDrop 2000 spectrophotometer. 
Values of A260 were taken for the calculation of total RNA amount following the fomular of 
1 A260 unit is equivalent to 40 µg/ml RNA. The ratio of A260/A280 was taken into account to 
provide the purity of the RNA samples. Values between 1.8 ~ 2.0 were acceptable.     
 
3.4.2 Reverse transcription 
 
1 µg total RNA was reverse transcripted into cDNA with the ImProm-II™ Reverse 
Transcription System (Promega) including 0.5 µg random primer, 0.5 mM dNTPs, 5 units 
ImProm-II reverse transcriptase, 20 units RNasin inhibitor. The reverse transcription was 
carried out in a 20 µl reaction. The extension was performed at 25 ºC 5 min, 42 ºC 60 min 
and 70 ºC 15 min.   
 
3.4.3 Polymerase Chain Reaction (PCR) 
 
1 µl of cDNA solution was analyzed by PCR, containing 0.2 mM dNTPs, 0.5 µM of each 
primer; 2.5 units Taq polymerase. In PCR analysis, β-actin was included as housekeeping 
gene to normalize and standardize the expression of target genes. The overall hTERT gene 
was amplified with the primers of LT5 and LT6; the hTERT alternative splicing variants 
were amplified with the primers hTERT-2026F and hTERT-2482V; p21, p53 and CDK2 
genes were also analyzed, all primer sequences and PCR protocols are listed in table 5. 
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       Table 5. Primers for reverse transcription-PCR (RT-PCR) 
 
gene  primer sequence (5’-3’)  Amplification 
condition 
β - actin (for) 
β - actin (rev) 
CCTGGCACCCAGCACAAT 
GGGCCGGACTCGTCATAC 
94 ºC 15 s 
60 ºC 15 s          20 cycles 
72 ºC 30 s 
LT5 
LT6 
CGGAAGAGTGTCTGGAGCAA 
GGATGAAGCGGAGTCTGGA 
94 ºC 45 s 
60 ºC 45 s          33 cycles 
72 ºC 90 s 
hTERT-2026F 
hTERT-2482V 
GCCTCAGCTGTACTTTGTCAA 
CGCAAACAGCTTGTTCTCCATGTC 
94 ºC 15 s 
60 ºC 15 s          35 cycles 
72 ºC 30 s 
p21 (for) 
p21 (rev) 
TTTCTCTCGGCTCCCCATGT 
GCTGTATATTCAGCATTGTGGG 
94 ºC 15 s 
60 ºC 15 s          20 cycles 
72 ºC 30 s 
Cdk2 (for) 
Cdk2 (rev) 
CCTCCTGGGCTGCAAATA 
CAGAATCTCCAGGGAATAGGG 
94 ºC 15 s 
60 ºC 15 s          22 cycles 
72 ºC 30 s 
p53 (for) 
p53 (rev) 
TGCGTGTGGAGTATTTGGATG 
TGGTACAGTCAGAGCCAACCAG 
94 ºC 15 s 
60 ºC 15 s          20 cycles 
72 ºC 30 s 
 
All amplifications were preceded by an initial heating to 95 ºC for 2 min, and the extension at 
72 ºC for 10 min in the end.  
   
3.4.4 Agarose gel electrophoresis 
 
PCR products were subjected to electrophoresis in agarose/TAE gels. 5 µl of each PCR 
product was analyzed. The PCR products of β-actin, overall hTERT, p21, and CDK2 were 
loaded onto 1.2% agarose gel and allowed to run at 80 V for 15 min. The product of hTERT 
alternative splicing variants was loaded onto 2% agarose gel and allowed to run at 40 V for 
2.5 h in order to separate the variants bands properly. DNA bands were then visualized with 
ethidium bromide in the UV – transilluminator. Intensity of each band was determined by 
ImageJ software.  
  
3.4.5 Relative quantification PCR (Real-Time PCR) 
  
Real-Time PCR technology is a nowadays commonly used analysis method, which has been 
adapted to perform quantitative RT-PCR (Winer, Jung et al., 1999), and to quantify the 
amount of the interesting transcript. Compared to the PCR which is conducted by the normal 
standard protocol, the Real-time PCR is more efficient and accurate. Relative quantification 
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determines the changes in steady-state mRNA levels of a target gene across multiple samples 
and expresses it relative to the levels of an untreated control. The reference gene is often a 
housekeeping gene and can be co-amplified in the same tube in a multiplex assay or can be 
amplified in a separate tube. SYBER Green provides the simplest and most economical 
format for detecting and quantitating PCR products in real time PCR. Increasing the 
temperature leads to the melting of the double strands of DNA, and thereby decreasing Syber 
green fluorescence. The melting curve is a plot of fluorescence versus increasing temperature.   
         
1 µl cDNA solution was applied in 10 µl PCR reaction in capillaries, containing 1 × SYBR 
Green Master Mix (ABgene), 0.3 µM of each primer. β-actin was involved as housekeeping 
gene, a no-template control was also included in each setup as negative control. The PCR 
reaction was performed in LightCycler3 (Roche).The initial denaturation at 95 ºC 10 min, 
followed with 45 cycles: 95 ºC 10 sec; 60 ºC 10 sec. Then all crossingpoint (cp) values were 
assessed by using REST soft relative to the expression of housekeeping gene of β-actin. The 
primers which were used in Real Time PCR are listed in table 5.  
 
                     Table 6. Primers for relative quantification PCR 
 
gene  primer sequence (5’-3’)  
β - actin (for) 
β - actin (rev) 
CCTGGCACCCAGCACAAT 
GGGCCGGACTCGTCATAC 
2007hTERT-f 
2007hTERT-v 
ACGGCGACATGGAGAACAA 
CACTGTCTTCCGCAAGTTCAC 
p21 (for) 
p21 (rev) 
TTTCTCTCGGCTCCCCATGT 
GCTGTATATTCAGCATTGTGGG 
Cdk2 (for) 
Cdk2 (rev) 
CCTCCTGGGCTGCAAATA 
CAGAATCTCCAGGGAATAGGG 
p53 (for) 
p53 (rev) 
TGCGTGTGGAGTATTTGGATG 
TGGTACAGTCAGAGCCAACCAG 
      
 
3.5 PROTEIN ANALYSIS 
 
3.5.1 Preparation and quantitation of protein extacts 
 
The preparations and quantitation of protein for Western blot analysis please see 4.3.1, but 
The lysis buffer was replaced by NP40 lysis buffer. 
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3.5.2 SDS-Polyacrylamide-Gel-Electrophoresis (SDS-PAGE) 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a commonly used technique to 
separate proteins according to their molecular weights. Since different proteins with similar 
molecular weights may migrate differently due to their differences in secondary, tertiary or 
quaternary structure. SDS is an anionic detergent, which is taken to unfold the proteins from 
their primary structures, and binds to the polypeptide backbone in a ratio of ~ 1.4 g SDS per 
gram of protein. The bound SDS gives the proteins a net negative charge per unit mass, 
overwhelming the intrinsic electrical charge of the sample protein. Additionally, SDS 
disrupts secondary and tertiary structures. Altering amounts of acrylamide and cross-linker 
controls the pore size, and thus the sieving properties of the polyacrylamide gel. %T is the 
total weight of acrylamide and cross-linker expressed as the percentage of the total volume 
and %C is the weight of the cross-linker expressed as the percentage of the total weight of 
both the acrylamide and cross-liner. Homogeneous gels (with same %T and %C) offer best 
resolution while gradient gels (varying %T and constant %C) provide a wider linear 
separation of molecular weight, minimized diffusion and sharp protein spots. The most 
common buffer system uses glycine as the trailing ion as described by Laemmli (Laemmli, 
1970).  
 
In our research, 12% SDS-PAGE (40% acrylamide mix; 375 mM Tris-HCl, pH 8.8; 0.1 % 
SDS; 0.1 % APS; 0.04 % TEMED), 0.75 mm thick gels were prepared. After polymerization, 
25 µg of each protein sample was mixed with sample buffer upon the ratio of 4:1 and the 
mixture was heated at 65 ºC for 5 min,  then the mixture was loaded per lane in the gel and 
kept one lane was available for molecular-weight standards. The gel was run at a constant 
voltage of 150 V for about 4 – 5 h. Then the gel was removed carefully from the glass for the 
further western blotting analysis.  
 
3.5.3 Western Blotting 
 
Western blotting is an analytical method that involves the immobilization of proteins on 
membranes before detection using monoclonal or polyclonal antibodies. The method was 
first described by Towbin (Towbin, Staehelin et al., 1979), but the official name of western 
blot was announced until 1981 by Burnette (Burnette, 1981).   
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When the protein electrophoresis was finished, the proteins were transferred onto a PVDF 
membrane following the “sandwich” protocol. All layers were mounted on a transfer 
chamber, and submerged in transfer buffer. The transfer process was carried out at 48 V for 4 
hours. The PVDF membrane was removed from the chamber and incubated in blocking 
buffer overnight at 4 ºC. 
    
3.5.4 Immunological detection of target proteins       
  
The PVDF membrane was incubated with different primary antibodies at room temperature 
for 60 min. Then the membrane was washed three times in TBS-T buffer and then put into 
blocking buffer containing secondary antibody for 60 min. After all these steps, the PVDF 
membrane was washed for 30 min in TBS-T. Enhanced chemiluminiscence (ECL) detection 
was performed according to the manufacturer’s instructions. ECL is a common technique for 
a variety of detection assays in biology. This technique is based on the oxidation of a 
luminol-based substrate by horseradish peroxidase. The horseradish peroxidase is conjugated 
to the primary antibody or to the secondary antibody. Light emission can easily be captured 
and visualized by exposing the blot to film or the charge coupled device (CCD) camera of an 
imaging system (Wang and Ren, 2005). The density of each protein band was analyzed by 
using ImagineJ software.     
 
Table 7. Antibodies used in western blotting 
 
Antibodies used in Western Blot 
Primary antibodies 
Targets                 Origin                  Supplier 
actin C4 Mouse monoclonal IgG1 MP Biomedicals 
γH2AX-aa134-142 human Mouse monoclonal IgG1 UPSTATE 
p53 DO-1-aa11-25 human Mouse monoclonal IgG2a Santa Cruz 
p21-aa145-164 human Mouse monoclonal IgG1 BD Biosciences 
c-Myc, p67 Mouse monoclonal Santa Cruz 
Secondary antibodies 
Targets Conjugated Supplier 
Anti-mouse Horseradish peroxidase  dianova, mouse 115-035-062 
 
       
3.6 SA-β-gal ANALYSIS 
 
Senescence associated β-gal (SA- β-gal) staining technology was initially proposed by Dimri 
(Dimri, Lee et al., 1995), and became nowadays widely used method to detect senescent cells. 
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Lysosomal β-galactosidase activity can be detected in situ in most mammalian cells by 
means of a cytochemical assay normally carried out at pH 4 (Dimri, Lee et al., 1995; van der 
Loo, Fenton et al., 1998), and β-galactosidase activity displays specifically at pH 6 in 
senescent cells, but not in quiescent or terminally differentiated cells (Dimri, Lee et al., 1995). 
A production of blue-dyed precipitate is conducted in senescent cell by the cleavage of the 
chromogenic substrate X-Gal. 
3.6.1 Cell fixation 
 
Cell samples were prepared in 6-well plates. After the treatment, control and treated cells 
were washed in PBS. Cells were fixed for 3 min at room temperature in 1 ml of fixative 
solution (See Buffer and Solution). Cells were washed again in PBS after the fixation and 2 
ml of SA-β-gal staining solution was added into each well. The cells were incubated at 37 °C 
(CO2 free) for 8 - 16 hours depending on the cell type.  
 
3.6.2 β-gal activity detection by microscopy 
 
The plate was taken out of the incubator when the blue dye could be observed under the 
microscopy. The SA-β-gal staining solution was discarded, refilled up each well with proper 
volume of water. The blue dye was then observed and photographed under microscope with 
different magnificence. 
 
                                                                                                                                          Results 
                                                                                                                                                  47 
4 RESULTS 
 
4.1 CYTOTOXICITY OF HARMINE, EMETINE AND SANGUINARINE AGAINST 
HUMAN CANCER CELLS 
 
One of most outstanding characters of alkaloids is cellular cytotoxicity towards animals and 
humans. The cytotoxic effect can be generated when cell membranes become leaky or when 
elements of cytoskeleton are inhibited (Wink, 1993; Wink, 2007), and it occurs also as a 
result of the molecular interaction of an alkaloid with one or several important targets present 
in a cell (Fig.1)(Wink, 2007).  
 
In order to evaluate the cellular cytotoxic effects of harmine (1), emetine (2), and 
sanguinarine (3), several human cancer cells including MCF-7, HeLa, and SiHa were used.  
The cellular viability in control and in different human malignant cell lines in vitro was 
assessed with a microassay with tetrazolium salt (MTT) for quantitation of cells. The IC50 
values after 24 h exposure were calculated after 24 h exposure by using the software of IC50 
calculator (Microsoft Excel) (Fig 9a-i), and the data is presented in Table 8. In three 
independent assays the reduction of cancer cell viability was consistent. To compare the toxic 
potenties of the alkaloids, we applied further studied by using more specific concentration 
and prolonged treatment period in the same cells. Results showed that the alkaloids harmine, 
emetine, and sanguinarine exhibited a similar toxic effect in tested cells in a dose- and time-
dependent manner.  
 
The growth kinetics of all compound-treated cells initially differed from those of untreated or 
solvent treated control cells, regardless of the cell line used. The increasing concentrations of 
the compounds corresponded with the percentage of growth inhibition of all tested cells after 
different days of drug exposure. Harmine exhibited in vitro growth inhibitory activity against 
different cancer cell lines as determined in the MTT assay. During the exposure of harmine, 
the treated cells slowed their growth and showed an almost complete inhibition of 
proliferation after 24 h at the highest concentrations in all cells, the reduction of cell viability 
tested under highest concentration decreased to 37% in MCF-7 cell, 34% in HeLa cell, and 
33% in SiHa cell of untreated control (Fig. 10a-c). Fig. 9d-f shows the effect of emetine on 
cell viability of MCF-7, HeLa and SiHa cells after 72 h treatment. Percent of cell viability 
was clearly affected by emetine in a dose- and time-dependent manner. Compared with the 
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dose-effect of emetine on MCF-7 cell, HeLa and SiHa cells revealed less sensitivity 
presented in platforms in response to emetine treatment (Fig. 10e,f). Emetine reduced the cell 
viability to 16% in MCF-7 cell, 13% in HeLa cell, and 14% in SiHa cell after 72 h treatment 
under the highest concentration applied in each cell line. As shown by the MTT reduction 
assay, treatment of cancer cells with various concentrations of sanguinarine for 72 h resulted 
in a dose-dependent decrease in the cell viability, while the cell viability decreased to 8.5% 
in MCF-7 cell, 25% in HeLa cell, and 2.5% in SiHa cell, respectively. All rates were 
calculated under the highest concentration of sanguinarine applied in each cell line (Fig. 10g-
i).  
 
Our results showed that alkaloid compounds 1-3 treatment had different effects on growth 
kinetics for the entire time of treatment in either cell line. The concentrations which induced 
an reduction of cell viability approximately around 30% and 50% were selected and 
summarized in Table 9.  
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(I) Cytotoxicity of harmine, emetine, and sanginarine  in human cancer cells  
     (i) Cytotoxicity of harmine in cancer cells (24 h of exposure) 
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        Fig 9a. The cytotoxicity of harmine in MCF-7 cells (error bars represent ± SD). 
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          Fig 9b. The cytotoxicity of harmine in HeLa cells (error bars represent ± SD).  
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             Fig 9c. The cytotoxicity of harmine in SiHa cells (error bars represent ± SD). 
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             (ii) Cytotoxicity of emetine in human cancer cells (24 h of exposure) 
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         Fig 9d. The cytotoxicity of emetine in MCF-7 cells (error bars represent ± SD). 
                               
HeLa
Concentration (µM)
0.0001 0.001 0.01 0.1 1 10 100 1000
C
el
l v
ia
bi
lit
y 
(%
)
0
10
20
30
40
50
60
70
80
90
100
110
 
            Fig 9e. Cytotoxicity of emetine in HeLa cells (error bars represent ± SD). 
                            
SiHa
Concentration (µM)
0.0001 0.001 0.01 0.1 1 10 100 1000
C
el
l v
ia
bi
lit
y 
(%
)
10
20
30
40
50
60
70
80
90
100
110
 
            Fig 9f. Cytotoxicity of emetine in SiHa cells (error bars represent ± SD). 
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            (iii) Cytotoxicity of sanguinarine in human cancer cells (24 h of exposure) 
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            Fig 9g. Cytotoxicity of sanguinarine in MCF-7 cells (error bars represent ± SD).      
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            Fig 9h. Cytotoxicity of sanguinarine in HeLa cells (error bars represent ± SD). 
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             Fig 9i. Cytotoxicity of sanguinarine in SiHa cells (error bars represent ± SD). 
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 (II). Anti-proliferative effect of alkaloids on cancer cells 
(i) Anti-proliferative effect of harmine on human cancer cells 
                                                                    MCF-7 cell 
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Fig 10a. The inhibitory effect of harmine on MCF-7 cell proliferation. Cells 
were exposed to various concentrations of harmine (10 µM, 20 µM, 30 µM), 
DMSO treated control was included (error bars represent ± SD).      
 
                                                                         HeLa cell                                                         
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Fig 10b. The inhibitory effect of harmine on HeLa cell proliferation. Cells 
were exposed to various concentrations of harmine (10 µM, 20 µM, 30 µM, 40 
µM). DMSO treated control was included (error bars represent ± SD).  
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Fig 10c. The inhibitory effect of harmine on SiHa cell proliferation. Cells 
were exposed to various concentrations of harmine (10 µM, 20 µM, 30 µM, 40 
µM). DMSO treated control was included (error bars represent ± SD).  
 
                  (ii) Anti-proliferative effect of emetine on human cancer cells 
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Fig 10d. The inhibitory effect of emetine on MCF-7 cell proliferation. Cells 
were exposed to various concentrations of emetine (0.05 µM, 0.1 µM, 0.15 µM, 
0.2 µM, 0.25 µM, 0.5 µM, 1 µM, 1.5 µM and 2.5 µM) (error bars represent ± SD). 
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Fig 10e. The inhibitory effect of emetine on HeLa cell proliferation. Cells were 
exposed to various concentrations of emetine (0.05 µM, 0.1 µM, 0.15 µM, 0.2 µM, 
0.25 µM and 0.5 µM) (error bars represent ± SD).  
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Fig 9f. The inhibitory effect of emetine on SiHa cell proliferation. Cells were 
incubated with various concentrations of emetine (0.05 µM, 0.125 µM, 0.25 µM, 
0.5 µM, 1 µM, 2 µM) (error bars represent ± SD). 
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            (iii) Anti-proliferative effect of sanguinarine on human cancer cells 
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Fig 10g. The inhibitory effect of sanguinarine on MCF-7 cell proliferation. 
Cells were incubated with various concentrations of sanguinarine (0.25 µM, 0.1 
µM, 1 µM, 2 µM, 2.5 µM, 3 µM, 4 µM and 5 µM) (error bars represent ± SD). 
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Fig  10h. The inhibitory effect of sanguinarine on HeLa cell proliferation. 
Cells were incubated with various concentrations of sanguinarine (0.5 µM, 1 µM, 
2 µM and 2.5 µM) (error bars represent ± SD). 
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Fig  10i. The inhibitory effect of sanguinarine on SiHa cell proliferation. Cells 
were incubated with various concentrations of sanguinarine (0.1 µM, 0.25 µM, 0.5 
µM, 1 µM, 1.5 µM, 2 µM, 2.5 µM and 5 µM) (error bars represent ± SD). 
 
 
            Table 8. The IC50 values of alkaloids in human cancer cells (24 h of exposure) 
               
  Compound 
                        IC50 (µM) / Cell line 
MCF-7 HeLa SiHa 
  harmine 104.03 ± 6.71 73.37 ± 3.45 151.68 ± 8.44 
  emetine 1.96 ± 0.21 2.08 ± 0.26 2.77 ± 0.54 
  sanguinarine 2.22 ± 0.05 2.12 ± 0.30 1.66 ± 0.04 
    
       
         
            Table 9. The effect of alkaloids1-3 on HeLa cell proliferation 
 
Cell line Compound 
                   Inhibition efficiency 
Concentration (µM) cell growth inhibition (%) 
HeLa 
1, Harmine           30 28.24 ± 4.44 (48 h) 
2, Emetine           0.15 50.93 ± 7.69 (48 h) 
3, Sanguinarine           2 25.09 ± 7.05 (48 h) 
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4.2 THE EFFECT OF ALKALOIDS ON TELOMERASE ACTIVITY   
 
As we described earlier, usually anticancer drugs especially alkaloids are able to interact with 
several important targets which are present in a cell, such intercalation leads to a cell cycle 
arrest and/or cell death through influencing DNA replication, transcription or reverse 
transcriptase, etc (Wink, 2007). TRAP assay is widely used and a specific method for the 
evaluation of telomerase activity. Telomerase activity is then represented in PAGE gel as a 
ladder of bands differed by 6 base pair in length from each. In this study, the effect of 
harmine, emetine, and sanguinarine on cancer cell telomerase activity was investigated by 
using TRAP assay, and telomerase activity has been proved positively in MCF-7, HeLa, and 
SiHa cells (Okayasu et al., 1998; Kurvinen et al., 2006; Padmanabhan et al., 2006).  
 
4.2.1 The effect of harmine on human cancer cell telomerase activity 
 
To examine the effect of harmine on telomerase activity, human cancer cells were cultured 
with it in different concentrations for various time periods. The investigated concentrations in 
TRAP assay were based on the proliferation assay. Samples were collected and analyzed 
simultaneously. The results showed that compared to untreated cells, harmine caused a 
significant inhibition of the telomerase activity in MCF-7 cells, and the maximal repression 
was detected at 20 µM for 96 h (Fig 11A). The telomerase inhibition percentage was 
calculated from band intensity, the expression was decreased by 81.87% of untreated control, 
and the inhibition occurred in a dose- and time-dependent manner (Fig 11B,C). The 
investigation was performed in both HeLa and SiHa cells as well by using the same method. 
Harmine inhibited telomerase activity in both cell lines, but a severe decrease of telomerase 
activity was only detected in HeLa cells, the inhibition revealed as early as 24 h at 30 µM 
and became almost undetectable at 48 h by 87% reduction of telomerase activity of untreated 
control (Fig 12C). Compared to HeLa cell, harmine initiated a moderate inhibitory effect on 
SiHa cell, a decrease of telomerase activity was detected to 46.55% at the highest 
concentration of 30 µM at 48 h (Fig. 13). Taken together, the results indicate that harmine 
induces a significant inhibition in human cancer cells, the reduction was in time- and dose-
dependent manner in MCF-7 and HeLa cell lines (Fig 11B,C, Fig 12B,C). 
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Fig 11. The effect of harmine on telomerase activiy in MCF-7 cells. (A), nc: CHAPS 
buffer; pc: telomerase-positive control; C*, DMSO treated control; IC: internal control; lane 1, 
untreated control; lane 2-3, cells treated with 10, 20 µM of harmine, respectively; Graphical 
representation of telomerase activity from densitometric analysis in (B) time-dependent 
manner or (C) dose-dependent manner. Each point represents the mean value of telomerase 
activity ± S.D. from three independent experiments. 
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             A                           24 hr                      48 hr                   
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Fig 12. The effect of harmine on telomerase activiy in HeLa cells. (A), nc: CHAPS buffer; 
pc:   telomerase-positive control; C*, DMSO treated control; IC: internal control; lane 1, 
untreated cells; lane 2-4, cells were treated with 10, 20, 30 µM of harmine; Graphical 
representation of telomerase activity from densitometric analysis in (B) time-dependent 
manner or (C) dose-dependent manner. Each point represents the mean value of telomerase 
activity ± S.D. from three independent experiments.  
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                 A                                        24 hr                          48 hr 
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Fig 13. The effect of harmine on telomerase in SiHa cells. (A), nc: CHAPS buffer; pc:   
telomerase-positive control; C*, DMSO treated control; IC: internal control; lane 1, untreated 
cells; lane 2-4, cells were treated with 10, 20, 30 µM of harmine; Graphical representation of 
telomerase activity from densitometric analysis in (B) time-depedent manner or (C) dose-
dependent manner. Each point represents the mean value of telomerase activity ± S.D. from 
three independent experiments.      
 
4.2.2 The effect of emetine on telomerase activity in cancer cell 
      
To examine the effect of emetine on human telomerase, the same technique and analysis 
method were used with the cellular extracts of HeLa and SiHa cells. As the result showed in 
Table 9, emetine at 0.15 µM or 0.25 µM induced a common proliferative reduction of 50% in 
both cell lines after 48 h. Therefore, for the further assessment of telomerase activity, those 
two concentrations were taken as the highest concentration to be tested in HeLa and SiHa 
cells, respectively. As predicted in Fig 14A, a slight decrease of telomerase activity was 
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observed after the exposure of emetine at 0.15 µM in HeLa cells, and the reduction was not 
changed by the longer treatment period. The reduction was then calculated based on the 
intensity of each band as 27.72% and 30.85% of untreated control at 24 h and 48 h, 
respectively. The highest concentration of 0.25 µM induced a significant reduction of 
telomerase activity of HeLa cell (Fig. 14B). The analysis of telomerase inhibition suggests 
that emetine inhibits HeLa cell telomerase in dose-dependent manner. Compared with the 
inhibitory effect on HeLa cells, emetine exhibited a weaker inhibitory effect on SiHa cell 
telomerase (Fig 15A), the expression level was decreased to 90.10% after 48 h at 0.25 µM 
and the reduction was increased to 65.01% at the highest concentration of 0.5 µM. The rate 
was not altered significantly by the extended incubation period.    
                A                                      24 hr                              48 hr 
                            nc  pc        1     2     3     4    5     6             1     2     3    4    5    6      
                                            
 
B                                                                         C       
 
 
Fig 14. The effect of emetine on telomerase activity in HeLa cells. (A), nc: CHAPS buffer; pc: 
telomerase-positive control; IC: internal control; lane 1, untreated cells; lane 2-6 : cells were 
treated with emetine in turn in 0.05 µM, 0.1  µM, 0.15  µM, 0.2 µM, and 0.25 µM. Graphical 
representation of telomerase activity from densitometric analysis in (B) time-depedent manner or 
(C) dose-dependent manner. Each point represents the mean value of telomerase activity ± S.D. 
from three independent experiments.   
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Fig 15. The effect of emetine on telomerase  activity in SiHa cells. (A), nc: CHAPS 
buffer; pc: telomerase-positive control; IC: internal control; lane 1, untreated cells; lane 2, 
cells were treated with 0.125 µM of emetine; lane 3, cells were treated with 0.25 µM of 
emetine; lane 4, cell were treated with 0.5 µM of emetine. Graphical representation of 
telomerase activity from densitometric analysis in (B) time-depedent manner or (C) dose-
dependent manner. Each point represents the mean value of telomerase activity ± S.D. 
from three independent experiments.  
 
4.2.3 The effect of sanguinarine on HeLa cell telomerase  
 
Sanguinarine concentrations used in experiments of TRAP assay were indicated (Fig. 16). As 
showed in Fig 16, telomerase activity of HeLa cells was inhibited after 48 h treatment (Fig 
16A), the telomerase activity was decreased to 39.79% of untreated control at 2.5 µM at 48 h. 
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No reduction of telomerase activity was detected in lower concentrations (0.5 µM and  1 µM) 
of sanguinarine (Fig 16B,C).  
 
        A                                       24 hr                               48 hr 
                           nc   pc         1      2     3     4    5   C*               1     2     3     4     5   C*             
                                                 
 
     B                                                                      C                                                              
  
Fig 16. The effect of sanguinarine on HeLa telomerase activity. (A) nc: CHAPS 
buffer; pc: telomerase-positive control; C*, DMSO treated control; IC: internal control; 
lane 1, untreated cells; lane 2, cells were treated with 0.5 µM of sanguinarine; lane 3, 
cells were treated with 1 µM of sanguinarine; lane 4, cells were treated with 2 µM; lane 
5, cells were treated with 2.5 µM of sanguinarine (B) Sanguinarine inhibits HeLa cell 
telomerase in time-dependent manner. (C) Sanguinarine inhibits HeLa cell telomerase 
in dose-dependent manner. 
 
4.2.4 Harmine has no direct effect on the isolated telomerase protein 
 
In order to elucidate the underlying mechanism of harmine-induced telomerase inhibition in 
MCF-7 and HeLa cells, a set of cell-free TRAP assay was carried out with the isolated 
extract from the cells. The cell-free system has been routinely used as a reference in 
evaluating the effects of standard chemotherapeutic agents on telomerase activity in human 
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cancer cell lines (Mosmann, 1983; Raymond, 1996; Zhu, 1996). In this experiment, solution 
of harmine at 30 and 40 µM was added to the telomerase reaction mixture containing 0.5 µg 
cell extract of each cell line, the mixture was incubated at room temperature for various time 
periods, and the assay was run. Fig 17 illustrates that no alternation of telomerase activity 
was found in response to harmine treatment compared to the untreated and solvent control 
(Fig 17). Telomerase known as a heat-sensitive protein, in this experiment, its activity was 
eventually diminished accompanied with the extended experimental temperature, and 
completely disappeared at 24 h in all tested cell extracts due to the enzyme lability. Due to 
these results we concluded that the inhibition of telomerase activity was not caused by the 
direct interaction between harmine and the enzyme.  
A                                                                         B 
   nc   pc      1    2     3     4      5     6     7     8              nc   pc    1      2     3     4     5      6     7     8 
               
                     6              8            10           24                                      2             6            10           24 
 
                                 Time (h)                                                             Time (h)                                                                                
       
 
                      
                              
                                                         
                                                     
                                                         
 
 
 
 
 
 
 
 
 
 
1                         (30 µM – MCF-7)   
3        + harmine  
5                         (40 µM – HeLa) 
7 
 
2 
4         + DMSO   
6 
8 
Fig 17. Cell-free assessment of 
telomerase activity by TRAP assay. nc: 
CHAPS lysis buffer; pc: telomerase-
positive control. A, The assay with MCF-7 
extract; B, The assay with HeLa cell 
extract. 
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4.2.5 Harmine inhibits MCF-7 and HeLa cell telomerase through different mechanisms 
 
4.2.5.1 Harmine down-regulates the mRNA expression of hTERT 
 
hTERT is a critical determinant of telomerase for telomerase catalytic activity (Kanaya et al., 
1998; Snijders et al., 2004). The RNA template (hTR), as reported from different groups, is 
detectable in most of cells, including normal cells. However, several in vitro studies showed 
that hTR expression level was increased in response to the cellular stress (Yi et al., 1999). 
Our previous investigation showed that harmine inhibits MCF-7 and HeLa cell telomerase 
activity via other mechanisms than the enzyme directly. Therefore, we next focused on the 
transcriptional regulation study on harmine-treated cells by using RT-PCR and the relative 
quantification PCR (Real-time PCR) techniques.  
 
The investigation was split into two steps: in the first step, MCF-7 cells were treated with 
harmine in different concentrations (10, 20 µM) up to 48 h. In order to ensure equal amount 
of mRNA was reverse transcripted in all samples, β-actin control was used. PCR result 
showed that treatment of harmine at 10 µM did not alter the hTERT expression after 48 h, 
whereas a decrease was detected at 20 µM (Fig 18A). This result was later confirmed by the 
relative quantification PCR (Fig 19). Based on these results, the second step of analysis was 
performed. The cells were treated with the same concentration of harmine at 20 µM up to the 
various time periods (48 h, 96 h). A reduction of the hTERT expression was observed which 
stayed stable throughout the entire treatment time up to 96 h (Fig 18B), this result was also 
determined by the quantification PCR (Fig 20).  
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Fig 18. The overall expression of hTERT in response to harmine in MCF-7 cells. NC: 
untreated control; C*: DMSO control. A, The dose-effect study on the global expression of 
hTERT . B, The time-effect study on the global expression of hTERT. 
 
 
    
 
          
 
Fig 19. The relative quantification PCR anaylsis of hTERT expression in MCF-7 cells 
in dose-effect manner. The graph represents the fluorescence intensities versus cycle 
number where the PCR products were formed. Each curve representing an individual 
sample.  
 hTERT 
28 s (total RNA) 
18 s 
 actin 
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Fig 20. The relative quantification PCR anaylsis of hTERT expression in 
MCF-7 cells in time-effect manner. The graph represents the fluorescence 
intensities versus cycle number where the PCR products were formed. Each curve 
representing an individual sample. 
 
The cp values were taken from at least three independent experiments, and analyzed by using 
the software of REST2008 (Munich, Germany). The graphical representation shows that 
harmine down-regulates MCF-7 cell hTERT expression (Fig 20).  
 
                           
 
Fig 21. Real time PCR analysis of hTERT gene showing a down-regulation 
on treatment with harmine. Experiments were repeated three times 
independently. The column is represented as mean ± standard errors of the 
samples and is statistically significant (p48 h = 0.003, p96 h = 0.002). 
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4.2.5.2 Harmine altered all detectable transcripts of hTERT in MCF-7 cell  
 
We have found that harmine markedly inhibited the global transcription of hTERT, we then 
asked whether the splicing of hTERT was involved in the regulation of telomerase activity in 
harmine-treated MCF-7 cells. hTERT transcript has at least six alternate splicing sites (4 
insertion sites and 2 deletion sites) in different human cancer cells (Kilian et al., 1997; 
Meyerson et al., 1997), and all 4 insertions cause premature translation terminations. To 
examine expression of alternatively spliced hTERT with the full length functional and the 
defective RT region was examined using primers (hTERT_2026F, hTERT_2048R) spanning 
the RT region of hTERT (Fig 22A). This region contains potential α and β splicing sites. The 
hTERT mRNA with a full length transcript was identified as hTERT +α+β (fl). mRNAs 
containing a defective alternative splicing were identified as hTERT -α (α variant), hTERT -β 
(β variant), and hTERT -α-β (-α-β variant). Under our experimental conditions, the -α-β 
variant was permanently absent. Analysis of mRNA showed that all three detectable 
alternative splicing forms of hTERT transcripts were presented in untreated MCF-7 cells. In 
the dose-effect study, expression of the full-length variant mRNA decreased significantly in a 
dose-dependent manner after harmine treatment at 20 µM. Both α variant and β variant 
mRNA expression was also decreased (Fig 22B). In the time-effect study, all detectable 
variants including the full length, α variant and β variant mRNA were dramatically decreased 
upon treatment of harmine and became almost undetectable on at 96 h (Fig 22C). The 
variant’s distribution assay demonstrated the pattern of hTERT splicing was altered. Harmine 
decreased the expression of both the functional and two non-functional hTERT mRNAs, 
suggesting that hTERT splicing might not play a role in harmine-induced down-regulation of 
telomerase activity in MCF-7 cells. 
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Fig 22. Alternative splicing variant expression of hTERT in response to harmine in 
MCF-7 cells. C*: DMSO control. A, Genomic organization of the hTERT gene. Exons 
1–16 and alternative splicing insertions (I1–I4, indicated by asterisks) and deletions (-α 
and -β, indicated by solid lines) (Yi et al. 2001).B, The dose-effect study on the splicing 
pattern of hTERT expression.C, The time-effect study on the splicing pattern of hTERT 
expression. 
 
 
4.2.5.3 Harmine induces hTERT alternative splicing variant shifting in HeLa cell   
          
Since telomerase activity was affected dramatically by harmine in HeLa cells (Fig. 12A), a 
direct inhibition of the telomerase could be included. In order to find out the potential 
mechanism of telomerase regulation, a set of analysis was carried out by using the same 
techniques as in MCF-7 cells. However, data obtained from normal PCR and relative 
quantification PCR showed that no repression of the global transcription of hTERT was 
detected in HeLa cells (Fig 23a). We, therefore, asked whether modulation of the hTERT 
splicing pattern might be a potential mechanism of telomerase inhibition in the HeLa cells. 
Upon treatment of harmine,  an alteration of the hTERT splicing was observed at 24 h, which 
led to a slight decrease of the full length transcript (+α+β) and an moderate increase of the β 
variant, whereas no alternation was found on the expression of α variant (Fig 23b). Further 
fl 
-α 
 
-β 
Fl    (457 bp)       
-α    (421 bp)       
-β    (275 bp) 
-α-β (239 bp) 
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prolongation of the treatment of 48 h did not increase the effect of harmine on hTERT 
splicing. Such alternation on the splicing pattern of hTERT transcript would probably 
account for the harmine-induced down-regulation of the telomerase enzymatic activity.  
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                                    NC        24         48       C* 
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           b 
                                
 
 
 
Conclusion: harmine inhibits MCF-7 and HeLa cell telomerase activity through different 
mechanisms. Harmine induces a down-regulation on the hTERT mRNA expression in MCF-
7 cells, whereas it initiates an alternation of hTERT splicing in HeLa cells.  
 
4.3 HARMINE INDUCES ACCELERATED SENESCENCE IN MCF-7 CELL  
 
Harmine triggers a mild DNA damage response in MCF-7 cell through p53/p21 pathway. As 
we know both apoptosis and senescence have been linked to p53 status (Elmore et al., 2002; 
Offer et al., 2002), but the determinant remains unknown. MCF-7 cells lack a functional 
form of caspase 3 (Janicke et al., 1998), senescence might represent a default response in 
cells incapable of undergoing apoptosis. Even in other case that MCF-7 cells were 
manipulated to express caspase 3, cells also failed to undergo apoptosis (Janicke et al., 2001). 
Therefore, we speculated that harmine might induce an accelerated senescence in MCF-7 
cells. After harmine treatment, the cells were fixed and incubated with SA-β-gal buffer for 
about 10 hours until the blue dye could be observed under the microscope. Representative 
photomicrographs showing harmine-induced accelerated senescence of accelerated 
senescence induced by harmine exposure is presented in Figure 25. β-galactosidase 
fl 
α 
Fig 23. Alternative splicing 
variant expression of 
hTERT in response to 
harmine in HeLa cells. NC: 
untreated control; C*: DMSO 
control. a, The time-effect 
study on the global expression 
of hTERT. b, The time-effect 
study on the splicing pattern 
of hTERT expression. 
β 
hTERT 
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expression was present in the MCF-7 cells as early as 2 days (Fig 24b), and became intense 
and expressed in virtually every cell of the culture at 4 days (Fig 24d).Cells with positive dye 
were larger in size or multinucleated (indicated with arrows), both of which are 
morphological features indicative of a senescent state.The SA-β-gal staining was not detected 
or barely detected in untreated or solvent control cells. This result indicates that harmine 
induces MCF-7 cells enter accelerate senescence. The experiment was repeated at least twice.  
 
               
                              
                         
 
Fig 24. SA- β-gal analysis of MCF-7 cells after treatment of harmine. 
All cells were stained for SA- β-gal expression at day 2 and day 4 after 
treatment. a, untreated control MCF-7 cells; b, the SA- β-gal expression 
was detected at day 2; c, DMSO control; d, the SA- β-gal expression was 
detected at day 4. Original magnification, ×10. 
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  4.4 HARMINE TRIGGERS P53-MEDIATED DNA DAMAGE RESPONSE IN MCF-7  
CELLS    
 
We have found that harmine treatment triggers MCF-7 cell growth arrest, at the meantime, 
induces cells to enter senescence status. Cellular senescence involves the action of the tumor 
suppressor p53. We have previously demonstrated that prolonged growth arrest and the 
accelerated senescence response after exposure of MCF-7 cells to a one third lethal 
concentration (20 µM) for 96h. Next we assessed the status of the p53 senescence pathway 
by a series of immunoblot analysis of crude cell lysates to figure out the underlying pathway 
on the harmine-induced MCF-7 cell cycle arrest. The cells were cultured with harmine in a 
final contration of 20 µM and then cell samples were collected at different time points (12 h, 
24 h, 48 h, and 96 h). The first finding showed that the level of phosphorylation of H2AX 
(γH2AX) protein slightly enhanced at 48 h and jumped to near maximal levels at 96 h.  
Increase in p53 protein level was detected by immunoblot analysis as early as 12 h, 
accompanied with the increase of p21 protein, and reached near plateau levels up to 96 h (Fig 
25B). c-Myc is a transcriptional enhancer of hTERT through binding onto the E-box in the 
hTERT promoter (Greenberg, 1999; Greenberg et al., 1999; Wu et al., 1999). Moreover, it 
has been reported that c-Myc can induce DNA damage and interfere with p53-induced cell 
cycle arrest (Hermeking et al., 1995; Vafa et al., 2002). In this study, c-Myc was determined 
on its protein level as well. The result of western blot showed a moderate alternation of c-
Myc occurred during harmine treatment. The regulations of p53, p21, and c-Myc on protein 
levels were displayed in the relative intensity analysis (Fig 25C). None of the changes was 
observed in untreated or solvent control. 
 
Mounted evidence showed that p21 binds to and inhibits Cdk2/cyclin E complexes thereby 
arresting cells proliferation (Aprelikova et al., 1995; Sherr and Roberts, 1999). We then 
tested from transcription level whether the association of p21-CDK2 involved in MCF-7 cells 
that underwent harmine-induced cell cycle arrest. After harmine treatment of 20 µM, the 
cells were harvested at different time points (12 h, 24 h, 48 h, and 96 h). The consistent result 
was obtained by real-time PCR that p21 mRNA expression was up-regulated in time-
dependent effect, and the up-regulation revealed as early as 12 h and reached the highest 
amount at 96 h. The significant inhibition of Cdk2 was detected started at 48 h and stayed 
stable at 96 h (Fig 25A). Taken together, all these results indicated that harmine triggers a 
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mild DNA damage in MCF-7 cell, and inhibits cell proliferation through the p53/p21 
pathway prior to inhibiting Cdk2 activities. The result of expression of related genes was 
summarized in Table 10. 
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Fig 25. Increase in p53 protein level accompany mild DNA damage following prolonged 
exposure of harmine in MCF-7 cells. NC: untreated control; C*: DMSO control. (A) The total 
RNA extracted from MCF-7 cells that had been treated with 20 µM harmine for indicated length of 
time was analyzed by RT-PCR that recognize each of the indicated genes. (B) Total proteins 
extracted from MCF-7 cells that had been treated with 20 µM harmine for indicated length of time 
were immunoblotted with antibodies that recognize each of the indicated proteins. (C) Relative 
intensity measurement of p53, p21, and c-Myc proteins expression. The intensity values were 
standardized by the expression of actin and untreated control. 
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Table 10. The summary of relative quantification PCR result of MCF-7 
cell after harmine treatment in time- and dose-effect studies. 
  
                             Transcriptional regulation of genes on mRNA level  
           
 
           Gene 
                                 12 h     24 h      48 h     96 h           10 µM         20 µM 
 
 
 
 
 
 
 
 
 
 
 
 
hTERT 
(global)     
Time-effect (20 µM) Dose-effect (48 h) 
 p21 
Cdk2 
p53 
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5. DISCUSSION 
 
5.1 The cytotoxic and anti-proliferative properties of alkaloids on human cancer cells 
 
Alkaloids are a large group of nitrogen-containing secondary metabolites (SM). Many 
alkaloids possess strong toxic properties towards animals and human (Wink, 2007; 2008). 
The medicinal use of alkaloids could be regard as an exploitation of properties that originally 
had been selected and developed in an ecological or evolutionary context (Wink, 1993; 
Roberts and Wink, 1998). During the past decade, much attention has been drawn on the 
anticancer potenties of alkaloids. Alkaloids were first time introduced into clinic as early as 
1965 and some of them have been used as anticancer drugs over 40 years (Johnson et al., 
1963; Zhou and Rahmani, 1992; Graham et al., 2000).  
 
In our study, we have evaluated the cytotoxic and anti-proliferative effect of the alkaloids 
harmine, emetine, and sanguinarine on human cancer cells in vitro. Results obtained from 
MTT assay showed that these compounds significant exhibited cytotoxicity against human 
cancer cells and induce cell cycle arrest in dose- and time- dependent manner. Cytotoxicity 
occurs as a result of the molecular interaction of an alkaloid with one or more important 
targets present in a cell (Wink, 2007), for instance, targeting DNA, RNA, or associated 
enzymes (Roberts and Wink, 1998; Wink, 2007;2008). This targeting will directly or 
indirectly lead to cell death via apoptosis (Lansiaux et al., 2002; Möller et al., 2007a) or 
senescence (Riou et al., 2002; Gewirtz et al., 2008).  
 
Harmine is β-carboline alkaloid originally isolated from the plant Peganum harmala (Roberts 
and Wink, 1998; Wink and Wyk, 2008), the crude seeds of P. harmala are used in Chinese 
medicine for digestive tract tumor cure. Harmine showed a cytotoxic effect and anti-
proliferative effect against human cancer cells in our research. The similar results were 
gained from other groups as well (Ishida et al., 1999; Song et al., 2004). Harmine, as 
reported, can repress many intracellular targets, such as cytochrome P450 (Tweedie et al., 
1988), and DNA topoisomerase I (Funayama et al., 1996). The actual harmine-induced 
cytotoxicity remains elusive although it was lately reported that harmine inhibits Cdk 2 and 
Cdk 5 in vitro (Song et al., 2002). Data from our group showed that harmine can intercalate 
to double stranded DNA, and whereby it interrupts DNA replication. Thus, we speculate that 
harmine-induced cell cycle arrest might involve such interactions in vivo. The cytotoxicity of 
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emetine was especially marked in HeLa and SiHa cells in this study. Emetine showed a 
stronger cytotoxic effect in cells, and the IC50 values are very close between cell lines. 
Emetine was identified as the main alkaloid of Cephaelis acuminata (Roberts and Wink, 
1998; Wink and Wyk, 2008). In pharmacology and cell biology, emetine is frequently used 
as an inhibitor of protein biosynthesis in eukaryotic cells to block de novo protein synthesis 
(Grollman, 1966; Gupta and Siminovitch, 1976). The cytotoxic property of emetine has been 
examined since last century; it was reported to exhibit cytotoxic properties in murine tumor 
systems. The cytotoxicity caused by emetine has been described by caspase-dependent 
apoptosis in U937 (Kochi and Collier, 1993; Bicknell et al., 1994), A549-S cells (Watanabe 
et al., 2002; Möller et al., 2007a), and Jurkat T-cells (Möller et al., 2006). Sanguinarine is 
present in various plant species, but main resources are Chelidonium majus, Macleaya 
cordata, and Sanguinaria canadensis (Roberts and Wink, 1998; Dvorak and Simanek, 2007; 
Wink and Wyk, 2008). Sanguinarine was documented to suppress or modulate the function 
of various cellular enzymes, such as like NF-κB, protein kinase C (Gopalakrishna, 1995; 
Chaturvedi, 1997). We have observed that sanguinarine exhibited a strong cytotoxicity in 
cancer cells and it also significantly arrested the cell proliferation, the similar results were  
also found in normal cell (Malikova et al., 2006a), rat hepatocytes (Choy et al., 2008), as 
well as in many other cancer cell lines (Malikova et al., 2006a). In various cell models, 
sanguinarine was found to cause DNA damage (Kaminskyy et al., 2008; Matkar et al., 2008), 
to modulate expression of proteins involved in regulating the cell cycle (Lee et al., 2008) and 
apoptosis (Weerasinghe et al., 2006). In some other reports, sanguinarine has been identified 
to reveal a strong DNA intercalating and reverse transcriptase inhibitory properties 
(Schmeller et al., 1997), and the DNA intercalation might be responsible for the mutagenic 
and even carcinogenic effects of this compound (Hakim, 1968). In summary, we have shown 
the cytotoxicity of harmine, emetine, and sanguinarine in human cancer cells. Although all 
these compounds revealed strong cytotoxic effect against human cancer cells and induced 
cell growth arrest, the underlying mechanisms may not be the same and need to be verified in 
further research. 
 
5.2 The effect of alkaloids on human telomerase  
 
Telomerase is ribonucleoprotein complex, which is detectable in 85–90% of human cancers 
and over 70% of immortalized human cell lines (Kim et al., 1994; Shay and Bacchetti, 1997), 
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and undetectable in normal somatic cells. The elevated level of telomerase has been 
identified as a characteristic feature of cancer cells that leads to immortality (Greider, 1998b). 
The evidence showed that the inhibition of telomerase activity led to the interruption of the 
genomic stability as well as cell growth arrest (Shay and Bacchetti, 1997). Telomerase, 
therefore, has been proposed as an important marker for tumorigenesis and is a potentially 
highly selective target for the development of anti-cancer agents (Rezler et al., 2002). 
 
The studies previously claimed that some alkaloids possess the inhibitory property on human 
telomerase, these alkaloids including berbamine (Ji et al., 2002), chelidonine (Noureini and 
Wink, 2009) and 9-hydroxyellipticine (Sato et al., 1998). However, little is known about 
harmine, emetine, or sanguinarine. In our study, we attempted to evaluate the effect of these 
alkaloids on human telomerase. The results obtained from TRAP assay showed that all these 
alkaloids displayed an inhibitory effect on human telomerase activity, but the inhibitory rates 
were quite different. (i) Harmine exhibited the most significant inhibition on human 
telomerase in MCF-7 and HeLa cell, the inhibitory rates were 82% and 87% of untreated 
control, respectively (Fig 11,12), whereas it caused a weaker inhibition on SiHa cell 
telomerase of 54% of untreated control (Fig 14). So far, the underlying mechanisms related 
to this result hve not been documented yet. However, results obtained from different groups 
showed that harmine is a promising cell proliferation inhibitor against cancer cells and 
significantly inhibits the activity of Cdk2 and Cdk4 in vitro (Song et al., 2004; Jimenez et al., 
2008). During the past years, many studies have tried to build up a linkage between 
telomerase expression and the sensitivity of cytotoxic drugs, but no direct correlation has 
been discovered till now (Akiyama et al., 1999; Cressey et al., 2002). Our observation is 
suggesting the cellular cytotoxicity which is caused by harmine is due, at least partially, to 
the inhibition of telomerase in those cancer cells. (ii) Emetine revealed a moderate inhibition 
on HeLa cell telomerase, and had a weak inhibitory effect on SiHa cells. Emetine, as reported 
possess strong toxicity, the data obtained from our other research showed that emetine is a 
promising apoptosis inducer in leukemia cells (Möller et al., 2007a; Möller and Wink, 
2007b). Some researchers have argued that telomerase might play a role in cellular resistance 
to apoptosis. For example, cisplatin known as telomerase inhibitor (Burger et al., 1997) 
triggered a halt of cell-cycle progression, telomere loss, and apoptosis (Ishibashi and Lippard, 
1998). Even in some case, without altering the telomerase activity, the cells undergoing 
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apoptosis after treatment of paclitaxel in murine melanoma cells (Multani et al., 1999) and in 
human pharynx cancer cells (Mo et al., 2003). Therefore, we speculate that the signaling 
pathway of cellular apoptosis may explain the inhibition of cell proliferation (Fig 10c,d) and 
telomerase activity which were induced by the emetine treatment. (iii) The alkaloid 
sanguinarine is known for its anticancer properties and possesses the potential for selective 
elimination of cancer cells.  
 
Telomeres are located on the each end of chromosome, protecting chromosome ends from 
fusion, recombination problems.  It has recently been suggested that within a population of 
cells there are large variations in telomere lengths, and the shortest telomeres are the most 
sensitive and lethal for cell viability (Hemann et al., 2001). Single stranded telomeric DNA 
sequences can be driven by the formation of guanine-quartets, forming an inter- or 
intramolecular G-quadruplex (Williamson, 1994; Simonsson, 2001). The human single-
stranded telomere end, which can potentially fold into a number of four-repeat quadruplexes, 
is far longer and more stable than in many other vertebrates, and mainly form two types of 
intramolecular G-quadruplex in vitro (Parkinson et al., 2002). A dynamic equilibrium at 
telomere ends between single-stranded and various types of folded telomeric repeats has been 
demonstrated (Griffith et al., 1999), telomerase itself will force this equilibrium towards 
single-strandedness at replication, since only then can template hybridisation and the 
synthesis of telomeric repeats on to 3' ends take place (Cuesta et al., 2003). A number G-
quadruplex ligands have been reported are able to inhibit telomerase through quadruplexes 
binding, termed intercalation (Cuesta et al., 2003). The potential role of quadruplexes in vivo 
has been highlighted with the recent development of therapeutic strategies designed to 
stabilize telomeric ends as G-quadruplex structures using specific small molecules, which 
can destabilize telomere maintenance in tumour cells (Parkinson et al., 2002).  
 
Alkaloid-based ligands like berberine and its synthetic derivative have been examined for G-
quadruplex binding and their ability to inhibit telomerase (Franceschin et al., 2006). Results 
show that these molecules have selectivity for G-quadruplex compared with duplex DNA, 
and that their aromatic moieties play a dominant role in quadruplex binding (Amit et al., 
2010). The selected alkaloids harmine, emetine, and sanguinarine have been investigated in 
our lab previously. The results obtained from our group and other groups showed that they 
are ability to intercalate DNA in vitro (Duportail, 1981; Schmeller et al., 1997; Wink et al., 
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1998; Wink, 2007), the strongest effects were detected for sanguinarine, followed by harmine, 
and emetine (Wink et al., 1998). However, in this study, we have found that harmine 
displayed a stronger inhibition on HeLa telomerase than that of sanguinarine, and the 
repression appeared obviously as early as 24 h (Fig. 12 and 13). One may argue that the 
inconsistent results might base on the low concentration of sanguinarine assessed in 
telomerase assay. The selected concentrations of harmine and sanguinarine for TRAP assay 
were according to the cell survival assay, in order to ensure the cell viability remaining 70% 
under treatments of both alkaloids (Table 9), and also different types of cell showed various 
sensitivities in response to the treatment of same compound. Data obtained from the half-life 
assessment indicates that telomerase is a highly stable molecule, with a half life > 24 hours in 
general (Holt et al., 1997). Shawn. et al have made a conclusion after evaluating the 
relationship between cell cycle regulation and telomerase activity in different human cancer 
cells, that telomerase activity generally correlates with growth rate and is repressed in cells 
that exit the cell cycle (Holt et al., 1997). Therefore, we speculate that harmine may trigger 
additional mechanisms simultaneously to facilitate the inhibition of telomerase activity in 
HeLa cell. The regulation and/or repression may thus include mechanisms such as the direct 
physical interaction of telomerase with regulatory proteins or degradation of the RNA or 
protein components. Moreover, all these compounds showed an inhibitory effect on reverse 
transcriptase in vitro within a range from 0.03 mM to 0.5 mM (Wink et al., 1998).  Taken 
together, all our data suggest that the alkaloids harmine, sanguinarine, and emetine can 
partially inhibit human telomerase through a fashion of intercalation, although the direct 
evidence of in vivo study needs to be further proved. 
 
5.3 The transcriptional regulation of hTERT expression in MCF-7 and HeLa cells 
 
Among all subunits of telomerase, the most important component responsible for the 
enzymatic activity of telomerase is hTERT (Meyerson et al., 1997; Nakamura et al., 1997). 
A tight link has been established between the transcriptional level of hTERT and telomerase 
activity (Bodnar et al., 1998; Takakura et al., 1998; Kyo et al., 1999). Therefore, to evaluate 
the regulatory expression of hTERT will lead to a better understanding of telomerase 
regulation in human tumors. Due to the fact that harmine induced a severe decrease of 
telomerase activity in both MCF-7 and HeLa cells, therefore, we preceded our research in the 
further step on these two cell lines.  
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We have detected previously that harmine exposure led to a dramatic suppression of 
telomerase activity in MCF-7 and HeLa cells, respectively. In MCF-7 cells, the significant 
inhibition of telomerase activity was observed at 96 h, it was at least 24 h after down-
regulation of hTERT mRNA expression, which was detected at 48 h. This is consistent with 
the observation that the half-life of hTERT is approximately 24 h (Holt et al., 1996b) and 
suggests that telomerase repression is achieved at the transcriptional level of hTERT. 
However, no alternation of hTERT on mRNA level was observed in HeLa cells.  
 
Transcriptional activation has been considered a major mechanism for the regulation of the 
hTERT gene (Poole et al., 2001). However, the data obtained from our research and previous 
observations (Kim et al., 1994; Shay and Bacchetti, 1997) showed that the expression of 
hTERT does not explain every event of the inhibition of telomerase activity caused 
differently. Also, the presence of hTERT mRNA encoding functional or defective spliced 
isoforms has been demonstrated in several types of human cells (Kilian et al., 1997; Ulaner, 
1998; Ulaner et al., 1998; Liu et al., 1999). The splicing pattern of hTERT mRNA has been 
considered as part of a regulatory mechanism for telomerase activity, but the details are 
unclear. Only three spliced isoforms could be detected in our study, the full length, the α 
deletion, and the β deletion isoforms, the -α-β variant was permanently absent throughout this 
research. We found that the expression of all detectable isoforms of hTERT was decreased in 
MCF-7 cell (Fig 22), whereas in HeLa cells, the β deletion isoform was increased, the full 
length was slight decreased compared with untreated or solvent control, the expression of α 
deletion isoform was not altered (Fig 23). The β deletion variant has been observed in various 
cell types (Nakamura et al., 1997; Wick et al., 1999). It lacks two exons in its coding region, 
leading to a frameshift and premature termination of translation, resulting in dysfunction of 
the protein (Kilian et al., 1997).  Taken together, our research has found that harmine exert 
its inhibitory effect on human telomerase activity through different mechanisms depending 
on the cell type. 
 
5.4 The regulation of the expression of hTERT mRNA  
 
The results obtained in our study showed that p53 protein was overexpressed during harmine 
exposure, the increase displayed as early as 12 h and stayed stable throughout the entire 
treatment period. Such alternation accompanied with an overexpression of p21 and an 
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eventual decrease of c-Myc as well (Fig 25). At the meantime, the result of semi-
quantification PCR showed that the significant repression of the hTERT expression was 
detected at 48 h, it was at least 24 h later than the overexpression of p53, which suggest that 
MCF-7 cells lacking hTERT expression were more sensitive to cell cycle arrest and/or cell 
death induced by harmine. Moreover, the overexpression of wild-type p53 was observed to 
down-regulate telomerase enzymatic activity through transcriptional repression of hTERT 
independent of its effects on cell growth arrest and apoptosis (Gollahon et al., 1998; 
Kusumoto et al., 1999). Moreover, normal human breast epithelial cells transfected with a 
p53 mutant became immortalized and were reactivated for telomerase (Gollahon and Shay, 
1996), which suggest the existence of a p53-dependent regulatory pathway for 
hTERT/telomerase control in human cells. Thus, we argued that the hTERT expression is 
transcriptionally downregulated in our study, at least partially, upon the induction of wt p53 
in MCF-7 cells. Similarly, two recent studies showed that the overexpression of wt p53 
inhibited telomerase activity and hTERT expression in pancreatic cancer cells (Kusumoto et 
al., 1999; Kanaya et al., 2000).  
 
p53 can interact with different transcription factors or protein components to direct its 
transcriptional repression, such as the TATA binding protein (TBP) (Martin et al., 1993; 
Horikoshi et al., 1995), CCAAT-binding factor (CBF) (Matuoka and Chen, 2002) and Sp1 
(Gualberto and Baldwin, 1995; Bargonetti et al., 1997). Sp1 acts as a media in the interaction 
between p53 and hTERT. hTERT promoter does not contain any p53 binding sites due to the 
lacking of TATA motif. However, the serial deletion assays revealed that within the 181-bp 
core region of hTERT promoter that contains five GC-boxes (Takakura et al., 1999), Sp1 can 
transactive hTERT by directly binding onto these GC-boxes (Kyo et al., 2000). Abrogation 
of Sp1 bindings by substitution mutations resulted in a marked loss of transcriptional activity 
indicating that Sp1 is a critical transactivator possibly involved in the basal transcription of 
hTERT (Kanaya et al., 2000). The overexpressed p53 promote the formation of p53-Sp1 
complexes, which disrupt Sp1-hTERT promoter binding and unable Sp1 to transactivate the 
hTERT (Xu et al., 2000). The direct evidence of formation of p53-Sp1 complex was obtained 
by co-immunoprecipitat technique (Xu et al., 2000). 
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Except Sp1 binding sites, two canonical E-box elements were identified within the core 
region of hTERT promoter (Cong et al., 1999; Horikawa et al., 1999). Several groups have 
reported that c-Myc protein was able to bind the E-box directly by the electrophoretic 
mobility shift assay (EMSA) (Wu et al., 1999; Kyo et al., 2000). In this study, we have found 
that the down-regulation of hTERT expression accompanied by a gradual decrease of c-Myc 
protein in MCF-7 cells (Fig 25), and the similar phenomenon was appeared in the research as 
well (Cerezo et al., 2002). Different studies have found that overexpression of c-Myc protein 
led to a remarkable, E-box dependent increase in the hTERT promoter activity (Wu et al., 
1999; Kyo et al., 2000). Moreover, the overexpressed c-Myc could induce the expression of 
endogenous hTERT mRNA and telomerase activity in normal human cells (Wang et al. 1998; 
Greenberg et al., 1999), indicates c-Myc plays an important role in the transcriptional 
regulation of hTERT.  
 
We observed a down-regulation of hTERT transcription in MCF-7 cells after harmine 
treatment and that did not occur in HeLa cells, instead, harmine induced a frameshifting by 
the post-transcriptional regulation leading to a slight up-regulation of β variant of hTERT. So 
far, the underlying mechanisms of alternative splicing are not yet clear. Recent study showed 
that the oncoprotein E6 was able to induce the transcriptional activation of hTERT 
(Klingelhutz et al., 1996). E6 is known to bind p53 and to promote its degradation in cervical 
carcinoma cells (Scheffner et al., 1990; Klingelhutz, 1996). Some of the cellular E6-interact 
proteins, such as E6TP1 and E6AP (Gewin and Galloway, 2001) are speculated to be 
involved in the hTERT activation as well (Gao et al., 2001). Therefore, we speculated that 
E6 and its associated factors might be involved in telomerase regulation in HeLa cells in 
response to harmine treatment, but together with the molecular mechanism of the alternative 
splicing of hTERT need to be further investigated.  
 
5.5 Harmine induces a p53-associated DNA damage response in MCF-7 cells 
 
The result of western blot showed that the expression of γH2AX was significantly increased 
at 96 h in MCF-7 cells (Fig 25). The increase in γH2AX expression is an early sign of 
genomic event reflects induction of double strands breaks (Albino et al., 2004; Tanaka et al., 
2007). This finding suggests that harmine triggered DNA damage response in MCF-7 cells, 
and this hypothesis is confirmed by other investigation although harmine was used at doses 
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greater than in the present study. Boeira and Moura in their reports claimed that harmine was 
able to induce significant strand breaks in V79 cell by using the chromosome aberration test 
(Boeira et al., 2001; Moura et al., 2007). Moreover, harmine was also characterized to 
enhance the induction of chromosome aberrations and produce DNA breakage in mammalian 
cells in cultured mammalian cells (Sasaki et al., 1992; Boeira et al., 2001) by the 
intercalation of DNA (Meester, 1995; Taira et al., 1997; Balon, 1999). The same pattern of 
interaction was observed in our previous study as well (Wink, 2007). Moreover, harmine has 
been also identified to able to inhibit topoisomerase I (Cao et al., 2005; Wink, 2007) and 
blocking the enzyme from the breakage-rejoining action to repair DNA damage and fix 
mutations (Sasaki et al., 1992; Wang, 1998), though which to favor DNA strand breaks.   
 
Different studies implicated that p53 is a critical determinant of cell fate following certain 
types of DNA damage (Clarke et al., 1993; Liu and Kulesz-Martin, 2001). The p53 protein 
can sense DNA strand breaks and to halt cell cycle progression at G1 check point by 
activating p21 transcription on DNA damage signal (el-Deiry, 1993). In our study, a rapid 
increase of p53 was observed in MC-7 cells following the treatment of harmine. The 
overexpression was revealed as early as 12 h and stayed stable throughout the entire treating 
period (96 h). Such elevation accompanied by an induction of p21 on both mRNA level and 
protein level (Fig 25), the inhibitor of cycling-dependent kinase (Cdk). Based on the previous 
demonstration that the p53-induced increase of p21 during DNA damage only inhibits Cdk2 
activity, the inhibition of Cdk4 is through a different mechanism (Boulaire et al., 2000; 
Bartek and Lukas, 2001; Agami and Bernards, 2002). Therefore, we only investigated the 
expression of Cdk2 in harmine treated MCF-7 cells. The result showed that the expression of 
Cdk2 mRNA was repressed just as what we expected. This result is consistent with the 
previous studies that DNA damage-induced Cdk inhibition can be caused by induction of the 
Cdk inhibitor p21 by p53 (Eldeiry et al., 1993; Dulic et al., 1994). However, the decrease 
expression of Cdk2 mRNA could also be initiated through a direct inhibitory effect by 
harmine, because it has been claimed by Song et al. that harmine is specific inhibitor of Cdk2 
in a low dose by enzymatic assay in vitro (Song et al., 2004). Taken together, we conclude 
that harmine under our tested dose triggers DNA damage in MCF-7 cells and initiate cell 
cycle arrest via p53/p21 pathway.  
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5.6 Harmine initiates a DNA damage response and induces MCF-7 cells enter premature 
senescence 
Accelerated senescence is characterized by the rapid induction of an irreversible growth 
arrest and some morphological features, such as enlarged nuclear and flattened cell shape 
(See chapter 1.3). We have previously showed the permanent growth arrest of MCF-7 cells 
during the chronic treatment of harmine for 4 days, resulted in accelerated senescence based 
on β-galactosidase expression and cell morphology (Fig 24). 
 
A number of studies have described a state of accelerated senescence or stress-induced 
premature senescence in response to various treatments that induce DNA damage including 
ionizing radiation (Oh et al., 2001; Gorbunova et al., 2002), ultraviolet (UV) radiation 
(Chainiaux et al., 2002; Gorbunova et al., 2002), hydrogen peroxide generation (Gorbunova 
et al. 2002; Frippiat et al., 2003) and antitumour drugs such as cisplatin, adriamycin and 
camptothecin (Chang et al., 1999a; Elmore et al., 2002; Wang et al., 2004). It has been 
demonstrated that the signaling pathways driving replicative senescence and DNA damage-
induced accelerated senescence are very similar (Gewirtz et al., 2008). Both events involve 
the action of tumor suppressor p53 and pRB. Furthermore, some studies claimed the 
induction of accelerated senescence response was p53-dependent (Suzuki et al., 2001; 
Elmore et al., 2002). Harmine can induce apoptosis in a variety of experimental human 
cancer cell lines (Chen et al., 2005; Song et al., 2006; Jimenez et al., 2008). However, in this 
study, the result of flow cytometric analysis (data not shown) demonstrated that MCF-7 cells 
failed to undergo a primary apoptotic response; instead cells entered an accelerated 
senescence after the chronic exposure to harmine. Considering MCF-7 cells express wild-
type p53 but lack functional caspase 3 protein (Kurokawa et al., 1999), the induction of 
senescence during harmine treatment might be attributed to a combination of p53-mediated 
senescence and the inability to progress down the apoptotic pathway. Similar results obtained 
from other studies (Jones et al., 2005; Elmore et al. 2002), MCF-7 cells failed to undergo 
apoptotic cell death but underwent accelerated senescence after the exposure of ionizing 
radiation and adriamycin. However, when p53 protein was diminished by infection of HPV-
E6 oncogene , MCF-7-E6 cells entered delayed programmed cell death (Elmore et al., 2002). 
Different to replicative senescence, telomere shortening was rarely detected in accelerated 
senescence; instead, it was more associated with telomere dysfunction and/or alterations of 
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telomerase activity (Leteurtre et al., 1997; Joo et al., 1998; Neuhof et al., 2001; Wang et al., 
2004). In our study, although the telomere length of MCF-7 cells was not examined after 
harmine exposure, considering the terminal restriction fragment (TRF) assay only measures 
average telomere lengths and not individual telomeres, it is formally possible that a single 
shortened telomere could be responsible for the senescence response (Hemann et al., 2001; 
Von Zglinicki, 2003). Therefore, we speculate that the senescence induced by harmine was 
likely to attribute to the reduction in the protective function of the chromosome ends. As a 
result of harmine treatment, the chromosomal ends (especially the G-quadruplex structures) 
were preferentially targeted for DNA damage. Moreover, harmine as reported is able to 
inhibit the activity of topoisomerase I (Song et al., 2004; Wink, 2007), where single strand 
breaks accumulate and/or the stabilization of G-quadruplexes force deprotection at the 
telomere. 
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6. OUTLOOK  
 
Alkaloids comprise a class of secondary metabolites (SM) with fascinating properties.  They 
are not waste products but have evolved mainly as defense compounds against herbivores, 
also against microbes, competing other plants, and even against viruses. In this study, the 
alkaloids harmine, emetine, and sanguinarine have shown to elicit their anticancer properties 
via a number of mechanisms.  
 
• Cellular cytotoxicity 
• Anti-proliferative activity 
• Inhibit human telomerase 
• Modulating the gene expression through different pathways 
• Inducing cells enter premature senescence status 
 
However, much more remains unknown. For focusing on specific targets, there are still some 
works can be done based on these finding. For example, to analysis MCF-7 cell cycle was 
stopped at which phase? Although we have gained some results by using FACS assay, they 
still need to be further proved. Also, what are the potential mechanisms which trigger an 
alternative splicing shift of hTERT expression in HeLa cell?  
 
In general, there is an increasing interest in the discovery of novel antitumor agents from 
natural resources. Over 46% of newly approved drugs and new drug candidates for cancer 
therapy by Food and Drug Administration were of natural origin during the period from 1989 
to 1995. The medicinal use of alkaloids and other natural products could be concerned as 
exploitation of properties that originally had been selected and developed in an ecological or 
evolutionary context (Wink, 1993; Roberts and Wink, 1998). The right plants and 
concentrations become excellent means for the therapeutic treatment of illness, disease, and 
even cancer. Many cytotoxic compounds, such as pyrroles, pyrazines, imidazoles have been 
tested as novel antitumor agents (Wink, 2007). 
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